Pharmacology Books

2392 products


  • Natural BabyCare Pure and Soothing Recipes and

    Workman Publishing Natural BabyCare Pure and Soothing Recipes and

    5 in stock

    Book SynopsisGet your baby off to a great start with gentle and safe homemade lotions, powders, creams, and shampoos. In this informative guide to natural baby care, Colleen Dodt offers easy-to-follow aromatic recipes that make creative use of herbs and essential oils while avoiding harsh chemicals. With simple homeopathic remedies for a variety of ailments, Dodt provides plenty of suggestions for ensuring glowing health and creating a relaxing atmosphere that can enhance the magical bond between you and your baby.

    5 in stock

    £12.34

  • Healing Without Hurting Treating ADHD Apraxia and

    Changing Lives Press Healing Without Hurting Treating ADHD Apraxia and

    2 in stock

    Book SynopsisJennifer Kozek is a therapist who practices in Connecticut, and is also the mother of a son with Autism Spectrum disorders. After treating Evan bio-medically, along with other healing practices, Jennifer witnessed the kind of improvements that every parent of a similarly diagnosed child dreams of: Evan no longer grunts and screams, throws toys, hits others, or has mood swings. He no longer throws himself into fits of uncontrollable rage, listens to his teachers and responds appropriately. He copes better with changes in routine & makes eye contact more often. He no longer enters into a trance-like state and the list goes on. Evan is now a happy, well-adjusted, 7-year-old. It is the author's mission to reach the millions of parents who struggle to find healthier and more natural ways to treat their children's nuanced disorders. Healing without Hurting, includes a full menu of natural treatment options, including: A real world success story. Specific points highlighted in boxes. Tips

    2 in stock

    £22.46

  • Legare Street Press My Watercure as Tested Through More Than Thirty

    15 in stock

    Book Synopsis

    15 in stock

    £18.95

  • Cambridge University Press Sleep Deprivation Stimulant Medications and

    15 in stock

    Book SynopsisSleep Deprivation, Stimulant Medications, and Cognition provides a review, synthesis and analysis of the scientific literature concerning stimulant medications and neurobehavioral performance, with an emphasis on critically evaluating the practical utility of these agents for maintaining cognitive performance and alertness in sleep-deprived (but otherwise healthy) individuals. The book explores the nature of sleep loss-induced cognitive deficits, neurophysiologic basis of these deficits, relative efficacy and limitations of various interventions (including non-pharmacological), and implications for applying these interventions in operational environments (commercial and military). Readers of this volume will gain a working knowledge of: â Mechanisms contributing to sleep loss-induced cognitive deficits â Differential effects of stimulant compounds on various aspects of cognition â Considerations (such as abuse liability) when applying stimulant interventions in operational settings âTable of ContentsForeword: sustaining cognitive performance: a modern imperative David Dinges; Part I. Basic Mechanisms: Cognitive Performance and Sleep: 1. The true nature of sleep loss-Induced 'neurocognitive performance deficits' – a critical appraisal Thomas J. Balkin; 2. Using fMRI to study cognitive function and its modulation in sleep deprived persons – a selective overview Michael W. L. Chee and Su Mei Lee; 3. The neurochemistry of cognitive impairment following sleep loss Robert E. Strecker and James T. McKenna; 4. The genetic basis of individual vulnerability to sleep loss Phillip J. Quartana and Tracy L. Rupp; Part II. Stimulant Reversal of Cognitive Deficits: 5. Modafinil reversal of cognitive deficits during sleep loss Nancy J. Wesensten; 6. Utility of caffeine: evidence from the laboratory Michael H. Bonnet and Donna L. Arand; 7. Caffeine: mechanism of action, genetics and behavioural studies conducted in task simulators and the field Christina E. Carvey, Lauren A. Thompson, Caroline R. Mahoney and Harris R. Lieberman; 8. Stimulants in models of shift work and shift work disorder Jonathan R. L. Schwartz and Aaron M. Henley; 9. The potential for abuse of stimulants in chronically sleep-restricted populations Emma Childs and Harriet de Wit; 10. Cognition enhancers versus stimulants Megan St Peters and Martin Sarter; 11. Novel pathways for stimulant development: the histaminergic system John J. Renger; 12. Novel pathways for stimulant development: the hypocretin/orexin system Ravi K. Pasumarthi and Thomas S. Kilduff; Part III. Alternatives for Sustaining Cognitive Performance During Sleep Loss: 13. Light exposure for improving cognition during sleep loss and circadian misalignment Kenneth P. Wright, Jr, Tina M. Burke and Mark R. Smith; 14. Nutritional countermeasures for cognitive performance decrements following sleep deprivation Caroline R. Mahoney and Harris R. Lieberman; 15. The role of alertness monitoring in sustaining cognition during sleep loss Melissa M. Mallis and Francine O. James; 16. Sustaining neurobehavioral performance on less sleep: is SWS enhancement the key? Janine M. Hall-Porter and James K. Walsh; Part IV. Summary and Conclusions: 17. Use of stimulants in operational settings: issues and considerations Nicholas Davenport, Cheryl Lowry and Brian Pinkston; 18. Fatigue management: the art of the state Tracy L. Rupp, Nancy J. Wesensten and Thomas J. Balkin.

    15 in stock

    £109.00

  • Cambridge University Press Continuous Biopharmaceutical Processes

    Out of stock

    Book SynopsisThis innovative reference provides a coherent and critical view on the potential benefits of a transition from batch to continuous processes in the biopharmaceutical industry, with the main focus on chromatography. It also covers the key topics of protein stability and protein conjugation, addressing the chemical reaction and purification aspects together with their integration. This book offers a fine balance between theoretical modelling and illustrative case studies, between fundamental concepts and applied examples from the academic and industrial literature. Scientists interested in the design of biopharmaceutical processes will find useful practical methodologies, in particular for single-column and multi-column chromatographic processes.Table of ContentsPreface; 1. Introduction to biopharmaceutical processes; 2. Fundamentals of protein chromatography; 3. Counter-current separation processes; 4. Counter-current chromatography for the capture step; 5. Counter-current chromatography for the polishing steps; 6. Protein conjugation; 7. Protein aggregation in biopharmaceutical processes; 8. Conclusion; References; Notation; Index.

    Out of stock

    £999.99

  • John Wiley & Sons Inc DrugDrug Interactions for Therapeutic Biologics

    Out of stock

    Book SynopsisStrategize, plan, and execute comprehensive drug-drug interaction assessments for therapeutic biologics Offering both theory and practical guidance, this book fully explores drug-drug interaction assessments for therapeutic biologics during the drug development process. It draws together and analyzes all the latest findings and practices in order to present our current understanding of the topic and point the way to new research. Case studies and examples, coupled with expert advice, enable readers to better understand the complex mechanisms of biologic drug-drug interactions. Drug-Drug Interactions for Therapeutic Biologics features contributions from leading international experts in all areas of therapeutic biologics drug development and drug-drug interactions. The authors'' contributions reflect a thorough review and analysis of the literature as well as their own firsthand laboratory experience. Coverage includes such essential topics as: Table of Contents PREFACE ix ABOUT THE EDITORS xi CONTRIBUTORS xiii 1. DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS: A JOURNEY JUST BEGINNING 1 Honghui Zhou and Bernd Meibohm 2. PHARMACOKINETIC AND PHARMACODYNAMIC-BASED DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 5 Dan Lu, Sandhya Girish, Frank-Peter Theil, and Amita Joshi 3. DRUG INTERACTION ASSESSMENT STRATEGIES: SMALL MOLECULES VERSUS THERAPEUTIC PROTEINS 39 Shannon Dallas, Carlo Sensenhauser, Souvik Chattopadhyay, and Jose Silva 4. MODEL-INDEPENDENT AND MODEL-BASED METHODS TO ASSESS DRUG–DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 63 Di Wu and Jeffrey S. Barrett 5. UTILITY OF IN VITRO METHODS IN DRUG–DRUG INTERACTION ASSESSMENT AND PREDICTION FOR THERAPEUTIC BIOLOGICS 73 Theresa Nguyen, Narendra Kishnani, and Raymond Evers 6. USE OF ANIMAL MODELS FOR PROJECTION OF CLINICAL DRUG–DRUG INTERACTIONS FOR THERAPEUTIC PROTEINS 103 Eugenia Kraynov and Martin E. Dowty 7. THE COCKTAIL APPROACH AND ITS UTILITY IN DRUG–DRUG INTERACTION ASSESSMENTS FOR THERAPEUTIC PROTEINS 111 Alexander Jetter and Uwe Fuhr 8. LOGISTIC CONSIDERATIONS IN STUDY DESIGN FOR BIOLOGIC DRUG–DRUG INTERACTION ASSESSMENTS 119 Min Zhu and Yu-Nien (Tom) Sun 9. STATISTICAL CONSIDERATIONS IN ASSESSING DRUG–DRUG INTERACTIONS FOR THERAPEUTIC BIOLOGICS 139 Chuanpu Hu and Honghui Zhou 10. SCIENTIFIC PERSPECTIVES ON THERAPEUTIC PROTEIN DRUG–DRUG INTERACTION ASSESSMENTS 155 Hong Zhao, Lei Zhang, Kellie Reynolds, and Shiew-Mei Huang 11. DISEASE–DRUG–DRUG INTERACTION ASSESSMENTS FOR TOCILIZUMAB—A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR TO TREAT PATIENTS WITH RHEUMATOID ARTHRITIS 191 Xiaoping Zhang and Barbara J. Brennan 12. DRUG–DRUG INTERACTIONS FOR ETANERCEPT—A FUSION PROTEIN 207 Joan Korth-Bradley 13. DRUG INTERACTIONS OF CYTOKINES AND ANTICYTOKINE THERAPEUTIC PROTEINS 215 J. Greg Slatter, Larry C. Wienkers, and Leslie J. Dickmann 14. DRUG INTERACTIONS FOR GROWTH FACTORS AND HORMONES 239 Yow-Ming C. Wang and Tarundeep Kakkar 15. DRUG–DRUG INTERACTIONS FOR NUCLEIC ACID-BASED DERIVATIVES 257 Jian Wang and Hong Zhao APPENDIX: MONOGRAPHS FOR DRUG-DRUG INTERACTIONS OF THERAPEUTICS BIOLOGICS 275 Jocelyn Leu, Simone Kasek, Christine Li, Wararat Limothai, Dora Babu Madhura, Chetan Rathi, Sumit Rawal, Josiah Ryman, Margaret Thomson, Ashit Trivedi, Honghui Zhou, and Bernd Meibohm INDEX 351

    Out of stock

    £999.99

  • Handbook of LCMS Bioanalysis

    John Wiley & Sons Inc Handbook of LCMS Bioanalysis

    Out of stock

    Book SynopsisConsolidates the information LC-MS bioanalytical scientists need to analyze small molecules and macromolecules The field of bioanalysis has advanced rapidly, propelled by new approaches for developing bioanalytical methods, new liquid chromatographic (LC) techniques, and new mass spectrometric (MS) instruments. Moreover, there are a host of guidelines and regulations designed to ensure the quality of bioanalytical results. Presenting the best practices, experimental protocols, and the latest understanding of regulations, this book offers a comprehensive review of LC-MS bioanalysis of small molecules and macromolecules. It not only addresses the needs of bioanalytical scientists working on routine projects, but also explores advanced and emerging technologies such as high-resolution mass spectrometry and dried blood spot microsampling. Handbook of LC-MS Bioanalysis features contributions from an international team of leading bioanalytical scientistsTrade Review“In that, it serves as a source of information and of literature references for further in-depth reading. It is very useful to have but, like always, it does not give all answers to every question one may have.” (ChemMedChem, 1 June 2014)Table of ContentsPreface xi Contributors xiii Abbreviations xvii Part I Overview of LC-MS Bioanalysis 1 Roles of LC-MS Bioanalysis in Drug Discovery, Development, and Therapeutic Drug Monitoring 3 Steve Unger, Wenkui Li, Jimmy Flarakos, and Francis L.S. Tse 2 Overview: Fundamentals of a Bioanalytical Laboratory 15 Shefali Patel, Qiangtao (Mike) Huang, Wenying Jian, Richard Edom, and Naidong Weng 3 International Regulations and Quality Standards of Bioanalysis 29 Surendra K. Bansal Part II Current Understanding of LC-MS Bioanalysis-related Regulations 4 Current Regulations for Bioanalytical Method Validations 39 Mark E. Arnold, Rafael E. Barrientos-Astigarraga, Fabio Garofolo, Shinobu Kudoh, Shrinivas S. Savale, Daniel Tang, Philip Timmerman, and Peter van Amsterdam 5 Current Understanding of Bioanalytical Assay Reproducibility: Incurred Sample Reanalysis, Incurred Sample Stability, and Incurred Sample Accuracy 47 Manish S. Yadav, Pranav S. Shrivastav, Theo de Boer, Jaap Wieling, and Puran Singhal 6 LC-MS Bioanalytical Method Transfer 65 Zhongping (John) Lin, Wenkui Li, and Naidong Weng 7 Metabolites in Safety Testing 71 Ragu Ramanathan and Dil M. Ramanathan 8 A Comparison of FDA, EMA, ANVISA, and Others on Bioanalysis in Support of Bioequivalence/ Bioavailability Studies 83 Bradley Nash 9 A Comparison of the Guidance of FDA, OECD, EPA, and Others on Good Laboratory Practice 89 J. Kirk Smith 10 Current Understanding of Bioanalysis Data Management and Trend of Regulations on Data Management 97 Zhongping (John) Lin, Michael Moyer, Jianing Zeng, Joe Rajarao, and Michael Hayes 11 Regulatory Inspection Trends and Findings of Bioanalytical Laboratories 109 Frank Chow, Martin Yau, and Leon Lachman Part III Best Practice in LC-MS Bioanalysis 12 Assessment of Whole Blood Stability and Blood/Plasma Distribution of Drugs 129 Iain Love, Graeme T. Smith, and Howard M. Hill 13 Best Practice in Biological Sample Collection, Processing, and Storage for LC-MS in Bioanalysis of Drugs 139 Maria Pawula, Glen Hawthorne, Graeme T. Smith, and Howard M. Hill 14 Best Practices in Biological Sample Preparation for LC-MS Bioanalysis 165 Guowen Liu and Anne-Françoise Aubry 15 Best Practice in Liquid Chromatography for LC-MS Bioanalysis 185 Steve Unger and Naidong Weng 16 Best Practice in Mass Spectrometry for LC-MS 205 Richard B. van Breemen and Elizabeth M. Martinez 17 Use of Internal Standards in LC-MS Bioanalysis 217 Aimin Tan and Kayode Awaiye 18 System Suitability in LC-MS Bioanalysis 229 Chad Briscoe 19 Derivatization in LC-MS Bioanalysis 239 Tomofumi Santa 20 Evaluation and Elimination of Matrix Effects in LC-MS Bioanalysis 249 Bernd A. Bruenner and Christopher A. James 21 Evaluation and Elimination of Carryover and/or Contamination in LC-MS Bioanalysis 259 Howard M. Hill and Graeme T. Smith 22 Automation in LC-MS Bioanalysis 275 Joseph A. Tweed 23 LC-MS Bioanalysis of Drugs in Tissue Samples 297 Hong Gao, Stacy Ho, and John Williams 24 LC-MS Bioanalysis of Drugs in Urine 307 Allena J. Ji 25 LC-MS Bioanalysis of Unbound Drugs in Plasma and Serum 317 Theo de Boer and Jaap Wieling 26 LC-MS Bioanalysis of Drugs in Bile 327 Hong Gao and John Williams 27 LC-MS Bioanalysis of Intracellular Drugs 337 Fagen Zhang and Michael J. Bartels 28 LC-MS Bioanalysis of Endogenous Compounds as Biomarkers 353 Wenying Jian, Richard Edom, and Naidong Weng 29 LC-MS Bioanalysis of Drugs in Hemolyzed and Lipemic Samples 369 Min Meng, Spencer Carter, and Patrick Bennett 30 Best Practices in LC-MS Method Development and Validation for Dried Blood Spots 379 Jie Zhang, Tapan K. Majumdar, Jimmy Flarakos, and Francis L.S. Tse 31 LC-MS Method Development Strategies for Enhancing Mass Spectrometric Detection 391 Yuan-Qing Xia and Jeffrey D. Miller 32 LC-MS Bioanalysis-Related Statistics 403 David Hoffman 33 Simultaneous LC-MS Quantitation and Metabolite Identification in Drug Metabolism and Pharmacokinetics 417 Patrick J. Rudewicz Part IV Representative Guidelines and/or Experimental Protocols of LC-MS Bioanalysis 34 LC-MS Bioanalysis of Ester Prodrugs and Other Esterase Labile Molecules 431 Wenkui Li, Yunlin Fu, Jimmy Flarakos, and Duxi Zhang 35 LC-MS Bioanalysis of Acyl Glucuronides 447 Jin Zhou, Feng (Frank) Li, and Jeffery X. Duggan 36 Regulated Bioassay of N-Oxide Metabolites Using LC-MS: Dealing with Potential Instability Issues 461 Tapan K. Majumdar 37 Hydrolysis of Phase II Conjugates for LC-MS Bioanalysis of Total Parent Drugs 471 Laixin Wang, Weiwei Yuan, Scott Reuschel, and Min Meng 38 LC-MS Bioanalysis of Reactive Compounds 479 Hermes Licea-Perez, Christopher A. Evans, and Yi (Eric) Yang 39 LC-MS Bioanalysis of Photosensitive and Oxidatively Labile Compounds 491 Corey M. Ohnmacht 40 LC-MS Bioanalysis of Interconvertible Compounds 505 Nico van de Merbel 41 LC-MS Bioanalysis of Chiral Compounds 519 Naidong Weng 42 LC-MS Bioanalysis of Peptides and Polypeptides 535 Hongyan Li and Christopher A. James 43 LC-MS Bioanalysis of Nucleosides 551 Laixin Wang and Min Meng 44 LC-MS Bioanalysis of Nucleotides 559 Sabine Cohen, Marie-Claude Gagnieu, Isabelle Lefebvre, and Jérôme Guitton 45 LC-MS Bioanalysis of Steroids 573 Jie Zhang and Frank Z. Stanczyk 46 LC-MS Bioanalysis of Liposomal Drugs and Lipids 591 Troy Voelker and Roger Demers 47 LC-MS Bioanalysis of Proteins 601 Ziping Yang, Wenkui Li, Harold T. Smith, and Francis L.S. Tse 48 LC-MS Bioanalysis of Oligonucleotides 607 Michael G. Bartlett, Buyun Chen, and A. Cary McGinnis 49 LC-MS Bioanalysis of Platinum Drugs 629 Troy Voelker and Min Meng 50 Microflow LC-MS for Quantitative Analysis of Drugs in Support of Microsampling 639 Heather Skor and Sadayappan V. Rahavendran 51 Quantification of Endogenous Analytes in Biofluids by a Combination of LC-MS and Construction of Calibration Curves Using Stable-Isotopes as Surrogate Analytes with True Biological Control Matrices 649 Wenlin Li, Lucinda Cohen, and Erick Kindt Appendix 1 Body and Organ Weights and Physiological Parameters in Laboratory Animals and Humans 659 Appendix 2 Anticoagulants Commonly Used in Blood Sample Collection 661 Appendix 3 Solvents and Reagents Commonly Used in LC-MS Bioanalysis 663 Appendix 4 Glossary of Terms Used in LC-MS Bioanalysis 665 Index 673

    Out of stock

    £119.65

  • Antiplatelet Therapy in Cardiovascular Disease

    John Wiley and Sons Ltd Antiplatelet Therapy in Cardiovascular Disease

    1 in stock

    Book SynopsisEdited by a team of the world's leading interventional cardiologists and educators, this book gives the reader a clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents.Trade Review“Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.” (Kingbook73's Medical Ebook and Video Collection, 20 August 2014)Table of ContentsList of Contributors, viii Foreword, xix Preface, xxi Section I: Platelet biology and pathophysiology 1 Platelet Pathophysiology and its Role in Thrombosis, 3 Paul A. Gurbel and Udaya S. Tantry 2 Platelet Receptors and Drug Targets: COX-1, 8 Thomas Hohlfeld and Karsten Schror 3 Platelet Receptors and Drug Targets: P2Y12, 14 Marco Cattaneo 4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21 Eliano Pio Navarese and Jacek Kubica 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29 Ping Zhang, Lidija Covic, and Athan Kuliopulos 6 Role of Inflammation and Hypercoagulability in Thrombosis, 45 Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry Section II: Platelet function tests 7 Light Transmission Aggregometry, 53 Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58 Marc Laine, Franck Paganelli, and Laurent Bonello 9 VerifyNow P2Y12 and Plateletworks Assays, 65 Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg 10 Multiplate Analyzer, 82 Martin Orban and Dirk Sibbing 11 Shear Stress-Based Platelet Function Tests, 92 Nicoline J. Breet and Jurriën M. ten Berg 12 Thrombelastography and Other Novel Techniques, 102 Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel Section III: Antiplatelet pharmacology 13 Aspirin, 111 Karsten Schrör and Thomas Hohlfeld 14 Cilostazol, 117 Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park 15 Abciximab, 125 J. Emilio Exaire and Jorge F. Saucedo 16 Tirofiban, 131 Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm 17 Eptifibatide, 142 Nevin C. Baker and Ron Waksman 18 Ticlopidine, 150 Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo 19 Clopidogrel, 160 Andrzej Budaj 20 Prasugrel, 166 Christoph Varenhorst, Anna Oskarsson, and Stefan James 21 Elinogrel, 173 Matthew J. Chung and Sunil V. Rao 22 Cangrelor, 180 Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo 23 Ticagrelor, 193 Anna Oskarsson, Christoph Varenhorst, and Stefan James 24 Thrombin Receptor Antagonists, 198 Flavio de Souza Brito and Pierluigi Tricoci Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy 25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209 Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio 26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220 Joshua P. Loh and Ron Waksman 27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229 Michael A. Gaglia, Jr. and Ray V. Matthews 28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237 Ana Laynez and Ron Waksman 29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245 Aung Myat, Yousif Ahmad, and Simon R. Redwood 30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253 Sa'ar Minha and Ron Waksman 31 Bleeding Definitions, 259 Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran Section V: Antiplatelet Responsiveness 32 Personalizing Antiplatelet Therapy, 269 Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry 33 Aspirin Resistance, 277 Muthiah Vaduganathan and Eli I. Lev 34 Clopidogrel Resistance, 285 Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel 35 Genetics of Clopidogrel Poor Response, 293 Pierre Fontana and Jean-Luc Reny 36 Proton Pump Inhibitors and Clopidogrel, 300 Michael A. Gaglia, Jr 37 Other Drug Interactions with Clopidogrel, 306 Eric R. Bates Index, 314

    1 in stock

    £64.76

  • Predictive ADMET Integrated Approaches in Drug

    John Wiley & Sons Inc Predictive ADMET Integrated Approaches in Drug

    4 in stock

    Book SynopsisBy guiding in the application of techniques and tools for predicting ADMET outcomes in drug candidates, Predictive ADMET offers a road map for drug discovery scientists to generate effective and safe drugs for unmet medical needs.Trade Review“In conclusion, this volume fulfills its promise of being a very useful tool for guidance and diagnosis on ADMET matters, and I would recommend it to any scientist in the field.” (ChemMedChem, 1 June 2015) Table of ContentsPreface ix Contributors xi I Introduction to the Current Scientific, Clinical, and Social Environment of Drug Discovery and Development 1 Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D 3Laszlo Urban, Jean-Pierre Valentin, Kenneth I Kaitin, and Jianling Wang 2 Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-related ADRs 23Teresa Kaserer, Veronika Temml, and Daniela Schuster II Intelligent Integration and Extrapolation of Admet Data 3 ADMET Diagnosis Models 49Bernard Faller, Suzanne Skolnik, and Jianling Wang 4 PATH (Probe ADME and Test Hypotheses): A Useful Approach Enabling Hypothesis-driven ADME Optimization 63Leslie Bell, Suzanne Skolnik, and Dallas Bednarczyk 5 PK-MATRIX—A Permeability: Intrinsic Clearance System for Prediction, Classification, and Profiling of Pharmacokinetics and Drug–drug Interactions 89Urban Fagerholm 6 Maximizing the Power of a Local Model for ADMET-property Prediction 103Sebastien Ronseaux, Jeremy Beck, and Clayton Springer 7 Chemoinformatic and Chemogenomic Approach to ADMET 125Virginie Y. Martiny, Ilza Pajeva, Michael Wiese, Andrew M. Davis, and Maria A. Miteva 8 Multiparameter Optimization of ADMET for Drug Design 145Matthew D. Segall and Edmund J. Champness 9 PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models 167Hannah M. Jones and Neil Parrott 10 Emerging Full Mechanistic Physiologically Based Modeling 189Kiyohiko Sugano 11 Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery: A Translational Tool to Optimize Discovery Compounds Toward the Ideal Target-specific Profile 211Patricia Schroeder III Assessment and Mitigation of Critical Clinically Relevant Admet Risks in Drug Discovery and Development 12 In Vitro–In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds 235Christian Wagner and Jennifer B. Dressman 13 Evaluation of the Collective Impact of Passive Permeability and Active Transport on In Vivo Blood-brain Barrier and Gastrointestinal Drug Absorption 263Donna A. Volpe, Hong Shen, and Praveen V. Balimane 14 Integrated Assessment of Drug Clearance and Cross-Species Scalability 291Kevin Beaumont, James R. Gosset, and Chris E. Keefer 15 Practical Anticipation of Human Efficacious Doses and Pharmacokinetics using Preclinical In Vitro and In Vivo Data 319Tycho Heimbach, Rakesh Gollen, and Handan He 16 Management and Mitigation of Human Drug–drug Interaction Risks in the Drug Discovery and Development Phases 353Heidi J. Einolf and Imad Hanna 17 Integrated Assessment and Clinical Translation of In Vitro Off-target Safety Pharmacology Risks 397Patrick Y. Muller and Christian F. Trendelenburg 18 Integrated Risk Assessment of Cardiovascular Safety in Drug Discovery 407Gül Erdemli and Ruth L. Martin 19 Drug-induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools 433Donna M. Dambach 20 Carcinogenicity and Teratogenicity Assessment 467Hans-Jörg Martus, David Beckman, and Lutz Mueller 21 Nephrotoxicity: Development of Biomarkers for Preclinical and Clinical Application 491Frank Dieterle and Estelle Marrer IV Success Stories and Lessons Learned 22 Early Intervention with Formulation Strategies for Multidimensional Problems to Optimize for Success 507Stephanie Dodd, Christina Capacci-Daniel, Christopher Towler, Riccardo Panicucci, and Keith Hoffmaster 23 Cytochrome P450-mediated Drug Interaction and Cardiovascular Safety: The Seldane to Allegra Transformation 523F. Peter Guengerich 24 Clinical Toxicity Profile of VEGF Inhibitors 535Mark P. S. Sie and Ferry A. L. M. Eskens 25 Cardiomyopathy: Drug Induced and Predisposed 555Shirley A. Aguirre and Eileen R. Blasi 26 Safety Management by Pharmacokinetic Considerations: Ranibizumab (Lucentis) and Bevacizumab (Avastin) 569Nicole H. Siegel and Manju L. Subramanian Index 583

    4 in stock

    £121.46

  • Nanomedicine for Drug Delivery and Therapeutics

    John Wiley & Sons Inc Nanomedicine for Drug Delivery and Therapeutics

    4 in stock

    Book SynopsisThis book describes a broad area of nanomedicine which involves mainly applications, diseases, and diagnostics. The comprehensive coverage provides researchers, academics, and health specialists with a great tool, that includes techniques applicable to various uses.Table of ContentsPreface xv Part 1: Nanomedicine 1 1 High-technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition 3 Elvis Fosso-Kankeu, Pascaline Fontehand Ajay K.Mishra 1.1 Gene Therapy Including RNAHigh-Technology Against HIV 4 1.2 Metals and HIV Therapy 16 1.3 Conclusions 26 References 27 2 Emerging Nanomedicine Approaches for Osteochondral Tissue Regeneration 39 Author Lineis Missing 2.1 Introduction 39 2.2 Emerging NanomedicineApproaches 42 References 54 3 Synthesis of Poly(Methacrylate) Encapsulated Magnetite Nanoparticles via Phosphonic Acid Anchoring Chemistry and Its Applications Toward Biomedicine 63 B. Kothandapaniand Ajay K. Mishra 3.1 Introduction 64 3.2 Synthesis of Magnetite Nanoparticles 73 3.3 Application in Biomedical Fields 82 3.4 Conclusions 84 References 85 4 Potentiometric PVC Membrane Sensors and Their Analytical Applications in Pharmaceuticals and Environmental Samples at Micro- and Nano-level 87 Gamal Abel-Hafiz Mostafa 4.1 Introduction 87 4.2 Ion Selective Electrode 88 4.3 Glass Membrane Electrode 89 4.4 Characteristics of ISE 90 4.5 Preparation of PVC Membrane 94 4.6 Method of Preparation of the Liquid Membrane ISEs 96 4.7 Application of Ion Selective Electrodes in Pharmaceutical and Environmental Analysis Using 97 4.8 Conclusion 123 References 127 5 Bioceramics: Silica-based Organic-Inorganic Hybrid Materials for Medical Applications 135 Sadanand Pandey and Shivani B. Mishra 5.1 Introduction 136 5.2 Organic-Inorganic Hybrid Materials 141 5.3 Tissue Engineering 146 5.4 Other Organic-Inorganic Bioceramics for Medical Applications 150 5.5 Conclusion 156 5.6 Considerations and Future Directions 157 Acknowledgement 157 References 158 6 Recent Advances of Multifunctional Nanomedicines 163 Pradeep Pratap Singh and Ambika 6.1 Introduction 163 6.2 Nanomaterials of Biomedical Interest 164 6.3 Target-specificPharmacotherapy: Need for Nanocarrier Delivery Systems 165 6.4 Engineering of Pharmaceutical Nanosystems 166 6.5 Applications of Pharmaceutical Nanotools 180 6.6 Nanotoxicity 181 6.7 Future prospects 182 6.8 Conclusion 183 References 184 7 Nanomedicinal Approaches for Diabetes Management 189 Prashant Kumar Raiand Ajay Kumar Mishra 7.1 Introduction: The Motivation behind the Chapter 189 7.2 Type of Diabetes 191 7.3 Treatments for Diabetes 192 7.4 Why the Interest in Nanomedicine Research? 193 7.5 The Vision of Nanotechnology and its Clinical Applications for Diabetes 194 7.6 Summary 195 Acknowledgements 195 References 195 8 Polymeric Nanofibersin Regenerative Medicine 197 Narayan Chandra Mishra and Sharmistha Mitra (Majumder) 8.1 Introduction 197 8.2 Preparation of Nanofibers 199 8.3 RecentAdvances onApplication of Polymeric Nanofibersin Regenerative Medicine 201 8.4 Conclusions 222 References 222 Part 2: Drug Delivery and Therapeutics 227 9 Multifunctional Nano/Micro Polymer Capsules as Potential 229 Haider Sami, J. Jaishree, Ashok Kumar and Sri Sivakumar 9.1 Introduction 230 9.2 Synthesis of Polymer Capsules 232 9.3 Properties of Multilayered Polymer Capsules 237 9.4 Loading of Therapeutics 239 9.5 Stimuli-responsive Polymer Capsules 242 9.6 Multifunctional Hybrid Capsules 255 9.7 Targeted Polymer Capsules 267 9.8 BiomedicalApplications 268 9.9 Outlook and Future Prospects 274 References 274 10 Nanophosphors-Nanogold Immunoconjugates in Isolation of Biomembranes and in Drug Delivery 285 Dwijendra Gupta, Dhruv Kumar, Manish Dwivedi, Vijay Tripathi, Pratibha Phadke-Gupta and Surya Pratap Singh 10.1 Introduction 286 10.2 Nanoparticle Technology 287 10.3 The Versatility of Nanoparticles in Biological Sciences 288 10.4 Materials and Methods 293 10.5 Nanotags for Bio-labeling and Targeting: Nanophosphors or Quantum Dots 297 10.6 AFM Study of CdS and BSATagged ZnS-Mn Nanoparticles 302 10.7 Nano-Conjugates in Drug Delivery 304 10.8 Nanoparticle-mediated Drug Delivery and Nanotherapeutics 305 10.9 The Limitations of QDs 306 10.10 Summary 307 Acknowledgements 308 References 309 11 Cyclodextrin-based Nanoengineered Drug Delivery System 313 Jaya Lakkakula and Rui Werner Maçedo Krause 11.1 Introduction 314 11.2 Inclusion Complex Formation 316 11.3 Phase Solubility Relationships 318 11.4 Effect of Cyclodextrin on Drug Formulation 321 11.5 Cyclodextrin-based Drug Delivery 324 11.6 Cyclodextrins in Novel Drug Delivery Systems (DDS) 331 11.7 Conclusion 335 Acknowledgements 335 References 338 12 Medicinal Patches and Drug Nanoencapsulation 343 María H. Lissarrague, Hernan Garate, Melisa E. Lamanna, Norma B. D’Accorso and Silvia N.Goyanes 12.1 Introduction 343 12.2 Overview of Passive Skin Permeation (Passive Patches) 344 12.3 Recent Development on Skin Permeation 357 12.4 Drug Encapsulation 361 12.5 Triggered Release 369 12.6 Conclusions 374 References 374 13 Dendrimers: AClass of Polymer in the Nanotechnology for the Drug Delivery 379 Sunil K.Singh and Vivek K. Sharma 13.1 Introduction 379 13.2 Historical Origin of Dendrimers 380 13.3 Structure of Dendrimers 381 13.4 Terms Used in Dendrimer Chemistry 383 13.5 Types of Dendrimers 385 13.6 Application of Dendrimers 392 13.7 Dendrimers in Oral Drug Delivery 394 13.8 Dendrimers in Transdermal Drug Delivery 396 13.9 Dendrimers in Ocular Drug Delivery 398 13.10 Dendrimers inAnticancer Drug Delivery 399 13.11 Dendrimers in Cancer Diagnosis and Treatment 401 13.12 Conclusion 411 References 411 14 Designing Nanocarriers for Drug Delivery 417 Munishwar N. Gupta and Joyeeta Mukherjee 14.1 Introduction 417 14.2 Sizes, Shapes andAdvantages of Nanomaterials 418 14.3 Bioconjugation Strategies 421 14.4 Carbon Nanotubes 429 14.5 Drug Targeting 434 14.6 Future Perspectives 436 Acknowledgements 437 References 437 15 Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics 443 Alicia Sawdon and Ching-An Peng 15.1 Introduction 443 15.2 Composition, Formation and Characterization of Polymeric Micelles 444 15.3 Polymeric Micelles for Cancer Chemotherapy 450 15.4 Targeting Schemes 457 15.5 Polymeric Micelles for Diagnostics and Imaging 465 15.6 Conclusions 467 References 467 16 Nanoparticles-based Carriers for Gene Therapy and Drug Delivery 477 Marketa Ryvolova, Jana Drbohlavova, Kristyna Smerkova, Jana Chomoucka, Pavlina Sobrova,Vojtech Adam, PavelKopel, Jaromir Hubalek and Rene Kizek 16.1 Introduction 478 16.2 Targeted Delivery 478 16.3 Conclusion 494 References 494

    4 in stock

    £166.46

  • The Pharmaceutical Studies Reader

    John Wiley and Sons Ltd The Pharmaceutical Studies Reader

    1 in stock

    Book SynopsisThe Pharmaceutical Studies Reader is an engaging survey of the field that brings together provocative, multi-disciplinary scholarship examining the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace.Table of ContentsAcknowledgements vii 1 Introduction 1Jeremy A. Greene and Sergio Sismondo Part I Pharmaceutical Lives 17 2 The Pharmaceuticalisation of Society? A Framework for Analysis 19Simon J. Williams, Paul Martin and Jonathan Gabe 3 Pharmaceutical Witnessing: Drugs for Life in an Era of Direct]to]Consumer Advertising 33Joseph Dumit Part II New Drugs, Diseases, and Identities 49 4 Releasing the Flood Waters: Diuril and the Reshaping of Hypertension 51Jeremy A. Greene 5 Dep®ession and ConsumŠtion: Psychopharmaceuticals, Branding, and New Identity Practices 70Nathan Greenslit 6 BiDil: Medicating the Intersection of Race and Heart Failure 87Anne Pollock 7 Manufacturing Desire: The Commodification of Female Sexual Dysfunction 106Jennifer R. Fishman Part III Drugs and the Circulation of Medical Knowledge 121 8 Following the Script: How Drug Reps Make Friends and Influence Doctors 123Adriane Fugh]Berman and Shahram Ahari 9 Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster 133Kalman Applbaum 10 Pushing Knowledge in the Drug Industry: Ghost]Managed Science 150Sergio Sismondo 11 Transcultural Medicine: A Multi]Sited Ethnography on the Scientific]Industrial Networking of Korean Medicine 165Jongyoung Kim Part IV Political and Moral Economies of Pharmaceutical Research 179 12 Uncommon Trajectories: Steroid Hormones, Mexican Peasants, and the Search for a Wild Yam 181Gabriela Soto Laveaga 13 “Ready]to]Recruit” or “Ready]to]Consent” Populations? Informed Consent and the Limits of Subject Autonomy 195Jill A. Fisher 14 Clinical Trials Offshored: On Private Sector Science and Public Health 208Adriana Petryna 15 The Experimental Machinery of Global Clinical Trials: Case Studies from India 222Kaushik Sunder Rajan Part V Intellectual Property in Local and Global Markets 235 16 Intellectual Property and Public Health: Copying of HIV/AIDS Drugs by Brazilian Public and Private Pharmaceutical Laboratories 237Maurice Cassier and Marilena Correa 17 Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis’ Anti]Cancer Drug Glivec 247Stefan Ecks 18 Generic Medicines and the Question of the Similar 261Cori Hayden Index 268

    1 in stock

    £80.96

  • The Pharmaceutical Studies Reader

    John Wiley and Sons Ltd The Pharmaceutical Studies Reader

    1 in stock

    Book SynopsisThe Pharmaceutical Studies Reader is an engaging survey of the field that brings together provocative, multi-disciplinary scholarship examining the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace.Trade Review"...provides an in-depth look at the machinery that enables the continued expansion of pharmaceutical products, markets, and subjects." - Ellen Rubinstein for Anthropology Book Forum, Anthropology NewsTable of ContentsAcknowledgements vii 1 Introduction 1Jeremy A. Greene and Sergio Sismondo Part I Pharmaceutical Lives 17 2 The Pharmaceuticalisation of Society? A Framework for Analysis 19Simon J. Williams, Paul Martin and Jonathan Gabe 3 Pharmaceutical Witnessing: Drugs for Life in an Era of Direct]to]Consumer Advertising 33Joseph Dumit Part II New Drugs, Diseases, and Identities 49 4 Releasing the Flood Waters: Diuril and the Reshaping of Hypertension 51Jeremy A. Greene 5 DepRession and ConsumŠtion: Psychopharmaceuticals, Branding, and New Identity Practices 70Nathan Greenslit 6 BiDil: Medicating the Intersection of Race and Heart Failure 87Anne Pollock 7 Manufacturing Desire: The Commodification of Female Sexual Dysfunction 106Jennifer R. Fishman Part III Drugs and the Circulation of Medical Knowledge 121 8 Following the Script: How Drug Reps Make Friends and Influence Doctors 123Adriane Fugh]Berman and Shahram Ahari 9 Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster 133Kalman Applbaum 10 Pushing Knowledge in the Drug Industry: Ghost]Managed Science 150Sergio Sismondo 11 Transcultural Medicine: A Multi]Sited Ethnography on the Scientific]Industrial Networking of Korean Medicine 165Jongyoung Kim Part IV Political and Moral Economies of Pharmaceutical Research 179 12 Uncommon Trajectories: Steroid Hormones, Mexican Peasants, and the Search for a Wild Yam 181Gabriela Soto Laveaga 13 “Ready]to]Recruit” or “Ready]to]Consent” Populations? Informed Consent and the Limits of Subject Autonomy 195Jill A. Fisher 14 Clinical Trials Offshored: On Private Sector Science and Public Health 208Adriana Petryna 15 The Experimental Machinery of Global Clinical Trials: Case Studies from India 222Kaushik Sunder Rajan Part V Intellectual Property in Local and Global Markets 235 16 Intellectual Property and Public Health: Copying of HIV/AIDS Drugs by Brazilian Public and Private Pharmaceutical Laboratories 237Maurice Cassier and Marilena Correa 17 Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis’ Anti]Cancer Drug Glivec 247Stefan Ecks 18 Generic Medicines and the Question of the Similar 261Cori Hayden Index 268

    1 in stock

    £50.30

  • Prescribing Scenarios at a Glance

    John Wiley and Sons Ltd Prescribing Scenarios at a Glance

    10 in stock

    Book SynopsisPrescribing Scenarios at a Glance is an innovative resource which allows medical students and junior doctors to practise prescribing skills safely for themselves. Supporting those who wish to develop their prescribing knowledge and clinical reasoning, this book features 50 acute and on call scenarios in a hospital setting.Table of ContentsAcknowledgements 7 Dedication 7 List of abbreviations 8 How to use your textbook 10 About the companion website 13 Introduction: Practical prescribing scenarios 14 Please note that the prepared drug charts can be found in the accompanying workbook. Case Page Section 1: The acute take Case Drug chart Answer 1 An 82-year-old woman who requires venous thromboembolism prophylaxis 30 1.1 38 2 A 104-year-old woman with respiratory failure 30 2.1 40 3 A 64-year-old man with severe acute abdominal pain 31 3.1 41 4 A 55-year-old woman with atrial fi brillation 31 4.1 43 5 A 32-year-old man with community-acquired pneumonia 32 5.1 45 6 A 45-year-old woman with status epilepticus 32 6.1 47 7 A 27-year-old woman with suspected bacterial meningitis 33 7.1 48 8 A 31-year-old woman with paracetamol overdose 34 8.1 50 9 A 59-year-old man with acute pulmonary oedema 35 9.1 52 10 A 24-year-old woman with acute asthma 35 10.1 54 11 A 57-year-old man who has suddenly deteriorated 36 11.1 57 12 An 84-year-old man taking warfarin who has a headache 36 12.1 59 13 A 66-year-old man with acute coronary syndrome 37 13.1 61 14 A 67-year-old man with an exacerbation of COPD 37 14.1 64 Section 2: On call in the hospital Case Drug chart Answer 15 A 91-year-old man with hypoglycaemia 68 15.1 82 16 A 60-year-old woman requesting night sedation 68 16.1 83 17 A 62-year-old man with suspected opioid toxicity 69 17.1 84 18 A 58-year-old man who has low blood pressure 69 18.1 86 19 A 44-year-old woman who is ‘nil by mouth’ 70 19.1 88 20 A 59-year-old man with circulatory compromise 70 20.1 90 21 A 15-month-old girl with gastroenteritis 71 21.1 93 22 A 5-year-old boy with a painful right arm 71 22.1 94 23 A 12-hour-old boy with signs of sepsis 72 23.1 96 24 A 60-year-old man who has developed a hot joint 72 24.1 97 25 A 65-year-old man with hypokalaemia 73 25.1 99 26 A 69-year-old woman being treated with gentamicin 73 26.1 102 27 A 69-year-old man anticoagulated with warfarin 74 27.1 104 28 A 28-year-old woman with nausea 74 28.1 105 29 A 29-year-old man who is in pain following an operation 75 29.1 107 30 A 49-year-old man due to undergo surgery 75 30.1 110 31 A 79-year-old woman with acute kidney injury 76 31.1 112 32 An 85-year-old woman with hospital-acquired pneumonia 77 32.1 114 33 A 47-year-old man who has developed an abnormal liver profile 78 33.1 116 34 An 83-year-old man who develops diarrhoea 79 34.1 118 35 An 88-year-old man with hyperkalaemia 80 35.1 121 36 A 69-year-old woman with acute alcohol withdrawal 81 36.1 123 Section 3: Routine inpatient review Case Drug chart Answer 37 A 69-year-old woman with constipation 128 37.1 135 38 A 71-year-old man who has developed a tremor 128 38.1 136 39 An 81-year-old woman at risk of fragility fractures 129 39.1 138 40 A 23-year-old pregnant woman with pulmonary embolism 129 40.1 140 41 A 31-year-old man with increased seizure frequency 130 41.1 141 42 A 58-year-old man with diabetes mellitus treated with insulin 130 42.1 143 43 A 53-year-old man who wants to stop smoking 131 43.1 146 44 A 90-year-old woman on numerous medications 131 44.1 148 45 A 54-year-old woman with a peptic ulcer 132 45.1 150 46 A 64-year-old woman with chronic kidney disease 132 46.1 152 47 A 66-year-old man with palpitations 133 47.1 154 48 A 70-year-old man with ST-elevation acute coronary syndrome 133 48.1 156 49 A 49-year-old woman with chronic liver disease complaining of pain 134 49.1 158 50 An 89-year-old man approaching the end of life 134 50.1 160 Appendix 1 Antibiotic guidelines 163 Appendix 2 Case summaries 164 Index 166

    10 in stock

    £30.35

  • Closedform Solutions for Drug Transport through

    John Wiley & Sons Inc Closedform Solutions for Drug Transport through

    10 in stock

    Book SynopsisProvides solutions for two- and three-dimensional linear models of controlled-release systems Real-world applications are taken from used to help illustrate the methods in Cartesian, cylindrical and spherical coordinate systems Covers the modeling of drug-delivery systems and provides mathematical tools to evaluate and build controlled-release devices Includes classical and analytical techniques to solve boundary-value problems involving two- and three-dimensional partial differential equations Provides detailed examples, case studies and step-by-step analytical solutions to relevant problems using popular computational software Table of ContentsPreface ix Acknowledgements xi 1 Steady-State Analysis of a Two-Dimensional Model for Percutaneous Drug Transport 1 1.1 Separation of Variables in 2-D Cartesian Coordinates1 1.2 Model for Drug Transport across the Skin 3 1.3 Analytical Solution of the Diffusion Model in 2-D Cartesian Systems 4 1.4 Summary 6 1.5 Appendix: Maple, Mathematica, and Maxima Code Listings 6 Problems 10 References 12 2 Constant Drug Release from a Hollow Cylinder of Finite Length in Two Dimensions 13 2.1 Separation of Variables in 2-D Cylindrical Coordinates 13 2.2 Model for Drug Release from a Hollow Cylinder 15 2.3 Analytical Solution of the Transport Model in 2-D Cylindrical Coordinates 15 2.4 Summary 19 2.5 Appendix: Maple Code Listings 19 Problems 20 References 20 3 Analysis of Steady-State Growth Factor Transport Through Double-Layered Scaffolds 23 3.1 Governing Steady-State Transport Equations 23 3.2 Solution Procedure for Transport Through a Two-Layered Scaffold 25 3.3 Concentration Profile of Vascular Endothelial Growth Factor in Two Layers 31 3.4 Summary 32 3.5 Appendix: Maple Code Listings 33 Problems 37 References 38 4 Steady-State Two-Dimensional Diffusion in a Hollow Sphere 39 4.1 Separation of Variables and Legendre Polynomials in 2-D Spherical Coordinates 39 4.2 Model For 2-D Diffusion in a Sphere 43 4.3 Analytical Solution of 2-D Diffusion in Spherical Coordinates 46 4.4 Summary 49 4.5 Appendix: Maple, Mathematica, and Maxima Code Listings 49 Problems 56 References 57 5 Steady-State Three-Dimensional Drug Diffusion through Membranes from Distributed Sources 59 5.1 Separation of Variables in 3-D Cartesian Coordinates 59 5.2 Transport across the Membrane 61 5.3 Analytical Solution of the Diffusion Model in 3-D Cartesian Systems 63 5.4 Summary 68 5.5 Appendix: Maple Code Listings 69 Problems 73 References 73 6 Constant Drug Release from a Hollow Cylinder of Finite Length in Three Dimensions 75 6.1 Separation of Variables in 3-D Cylindrical Coordinates 75 6.2 Model For 3-D Drug Release from a Hollow Cylinder 77 6.3 Analytical Solution of the Transport Model in 3-D Cylindrical Coordinates 78 6.4 Summary 84 6.5 Appendix: Maple Code Listings 85 Problems 87 References 87 7 Sustained Drug Release from a Hollow Sphere in Three Dimensions 89 7.1 Method of Green’s Function in 3-D Spherical Coordinates 89 7.2 Model for Molecular Transport across the Wall of a Hollow Sphere 95 7.3 Analytical Solution of the Transport Model in 3-D Spherical Coordinates 96 7.4 Summary 97 7.5 Appendix: Maple, Mathematica and Maxima Code Listings 98 Problems 105 References 105 8 Analysis of Transient Growth Factor Transport Through Double-Layered Scaffolds 107 8.1 Laplace and Fourier-Bessel-based Methods in 2-D Cylindrical Coordinates 107 8.2 Governing Equations for Transport through Double-Layered Scaffolds 112 8.3 Concentration Profile of Vascular Endothelial Growth Factor in Two Layers 114 8.4 Summary 119 8.5 Appendix: Maple Code Listings 120 Problems 126 References 126 9 Molecular Diffusion through the Stomach Lining and into the Bloodstream 129 9.1 Laplace Transforms, Legendre Functions and Spherical Harmonics129 9.2 Spherical Diffusion in Three Dimensions 132 9.3 Analytical Solution of the Transient Transport Model in 3-D Spherical Coordinates 133 9.4 Summary 138 9.5 Appendix: Maple Code Listings 138 Problems 141 References 143 10 Diffusion-Controlled Ligand Binding to Receptors on Cell Surfaces 145 10.1 Weber’s Integral 145 10.2 Steady-State Diffusion-Limited Ligand Binding 148 10.3 Transient Diffusion-Controlled Ligand Binding in 2-D Cylindrical Coordinates 151 10.4 Summary 156 10.5 Appendix: Maple, Mathematica and Maxima Code Listings 156 Problems 167 References 168 11 Two-Dimensional Analysis of a Cylindrical Matrix Device with a Small Hole For Drug Release 169 11.1 Mathematical Modeling of Drug Transport through the Device 169 11.2 Drug Concentration Profile inside the Matrix 171 11.3 Normalized Cumulative Percentage of Drug Released 177 11.4 Summary 178 11.5 Appendix: Maple Code Listings 178 Problems 182 References 183 12 Three-Dimensional Drug Diffusion through Membranes from Distributed Sources 185 12.1 Governing Equations of the Transport Model 185 12.2 Analytical Solution of the Diffusion Model in 3-D Cartesian Systems 187 12.3 Average Dimensionless Concentration and Flux 194 12.4 Summary 194 12.5 Appendix: Maple and Mathematica Code Listings 195 Problems 207 References 207 13 Effective Time Constant for Two- and Three-Dimensional Controlled-Released Drug-Delivery Models 209 13.1 Effective Time Constant in Controlled-Release Drug-Delivery Systems 209 13.2 Intravitreal Drug Delivery using a 2-D Cylindrical Model 210 13.3 Analysis of a Rectangular Parallelepiped-Shaped Matrix with a Release Area 218 13.4 Summary 225 13.5 Appendix: Maple and Mathematica Code Listings 225 Problems 232 References 232 14 Data Fitting For Two- and Three-Dimensional Controlled- Release Drug-Delivery Models 233 14.1 Data Fitting in Controlled-Release Drug-Delivery Systems 233 14.2 Estimation of Diffusion Coefficient in a Solid Cylinder of Finite Length 234 14.3 Estimation of Diffusion Coefficient in a Rectangular Parallelepiped-Shaped Matrix 240 14.4 Summary 243 14.5 Appendix: Maple and Mathematica Code Listings 244 Problems 256 References 258 15 Optimization of Two- and Three-Dimensional Controlled-Released Drug-Delivery Models 259 15.1 Optimum Design of Controlled-Released Drug-Delivery Systems 259 15.2 Design of a 2-D Cylindrical Dosage Form with a Finite Mass Transfer Coefficient 260 15.3 Design of a Rectangular Parallelepiped-Shaped Matrix with a Finite Mass Transfer Coefficient 265 15.4 Summary 268 15.5 Appendix: Maple and Mathematica Code Listings 268 Problems 282 References 283 Index 285

    10 in stock

    £118.70

  • Neuroprotective Effects of Phytochemicals in

    John Wiley and Sons Ltd Neuroprotective Effects of Phytochemicals in

    10 in stock

    Book SynopsisPhytochemicals are naturally occurring bioactive compounds found in edible fruits, plants, vegetables, and herbs. Unlike vitamins and minerals, phytochemicals are not needed for the maintenance of cell viability, but they play a vital role in protecting neural cells from inflammation and oxidative stress associated with normal aging and acute and chronic age-related brain diseases.Neuroprotective Effects of Phytochemicals in Neurological Disordersexplores the advances in our understanding of the potential neuroprotective benefits that these naturally occurring chemicals contain. Neuroprotective Effects of Phytochemicals in Neurological Disordersexplores the role that a number of plant-based chemical compounds play in a wide variety of neurological disorders. Chapters explore the impact of phytochemicals on neurotraumatic disorders, such as stroke and spinal cord injury, alongside neurodegenerative diseases such as Alzheimer's and Parkinson's Disease, as well as neuropsychiatric disoTable of ContentsContributors xi Preface xix Acknowledgments xxiii 1 Use of Phytochemicals against Neuroinflammation 1Wei-Yi Ong, Tahira Farooqui, Christabel Fung-Yih Ho, Yee-Kong Ng, and Akhlaq A. Farooqui 2 Flavonoids in Transgenic Alzheimer’s Disease Mouse Models: Current Insights and Future Perspectives 43Angélica Maria Sabogal-Guáqueta, Edison Osorio, and Gloria Patricia Cardona-Gómez 3 Neuroprotective Effects of Polyphenols in Aging and Age-Related Neurological Disorders 65Giulia Corona and David Vauzour 4 Indian Herbs and their Therapeutic Potential against Alzheimer’s Disease 79Navrattan Kaur, Bibekananda Sarkar, Iqbal Gill, Sukhchain Kaur, Sunil Mittal, Monisha Dhiman, Prasad K. Padala, Regino Perez-Polo, and Anil K. Mantha 5 Garlic and its Effects in Neurological Disorders 113Akhlaq A. Farooqui and Tahira Farooqui 6 Effects of Extra-Virgin Olive Oil in Neurological Disorders 133Akhlaq A. Farooqui and Tahira Farooqui 7 Ginger Components as Anti-Alzheimer Drugs: Focus on Drug Design 149Faizul Azam 8 Phytomedicine: A Possible Tool for Alzheimer’s Disease Therapeutics 167Jai Malik 9 Effects of Phytochemicals on Diabetic Retinoneuropathy 199Mohammad Shamsul Ola, Mohd Imtiaz Nawaz, and Abdullah S. Alhomida 10 Herbal Drugs: A New Hope for Huntington’s Disease 213Jai Malik 11 Neuroprotective Properties of Dietary Polyphenols in Parkinson’s Disease 243Altaf S. Darvesh, McKenna McClure, Prabodh Sadana, Chris Paxos, Werner J. Geldenhuys, Joshua D. Lambert, Tariq M. Haqqi, and Jason R. Richardson 12 Potential of Polyphenols in the Treatment of Major Depression: Focus on Molecular Aspects 265Ashish Dhir 13 Effect of Phytochemicals on Diabetes-Related Neurological Disorders 283Abubakar Mohammed, Kanti Bhooshan Pandey, and Syed Ibrahim Rizvi 14 Neuroprotective Effects of Extra-Virgin Olive Oil and its Components in Alzheimer’s Disease 299Alaa H. Abuznait, Hisham Qosa, Loqman A. Mohamed, Yazan S. Batarseh, and Amal Kaddoumi 15 Protective Role of Black-Tea Extract in a Transgenic Drosophila Model of Parkinson’s Disease 317Yasir Hasan Siddique 16 Apitherapy: Therapeutic Effects of Propolis on Neurological Disorders 335Tahira Farooqui and Akhlaq A. Farooqui 17 Molecular Mechanisms behind the Beneficial Activity of Polyunsaturated Fatty Acids in Alzheimer’s Disease and Related Conditions 359Undurti N. Das 18 Prevention of Neuroinflammation by Resveratrol: Focus on Experimental Models and Molecular Mechanisms 377Justine Renaud and Maria-Grazia Martinoli 19 Modulation of the Estradiol and Neprilysin Pathways by Resveratrol in a Lipopolysaccharide Model of Cognitive Impairment 395Nesrine S. El Sayed 20 Neuroprotective Effect of Resveratrol in Cerebral Ischemia 407Ghosh Nilanjan, Ghosh Rituparna, Mandal C. Subhash, and Mahadeb Pal 21 Effects of Nobiletin in Animal Models of Cognitive Impairment: Current Insights and Future Perspectives 421Akira Nakajima, Yasushi Ohizumi, and Kiyofumi Yamada 22 Potential Neuroprotective Effects of Curcumin against Dementia 435Natascia Brondino, Laura Fusar-Poli, Cristina Panisi, and Pierluigi Politi 23 Neuroprotective Activity of Curcumin and Emblica officinalis Extract against Carbofuran-Induced Neurotoxicity in Wistar Rats 447Ramadasan Kuttan and P.P. Binitha 24 Potential Use of Curcuminoids for the Treatment of Alzheimer’s Disease 463Touqeer Ahmed, Sana Javed, Ameema Tariq, and Anwarul-Hassan Gilani 25 Prevention by Curcumin of Neuroinflammation in Intracerebral Hemorrhage 489Yujie Chen and Hua Feng 26 Effect of Polyphenols on Protein Misfolding 501Rona Banerjee 27 Molecular Mechanisms Involved in the Neuroprotective Action of Phytochemicals 515Aditya Sunkaria, Aarti Yadav, Sunil Kumar Sharma, and Rajat Sandhir 28 Nutraceuticals and Cognitive Dysfunction: Focus on Alzheimer’s Disease 561Virginia Boccardi, Clara Tinarelli, and Patrizia Mecocci 29 Summary and Perspective 581Tahira Farooqui and Akhlaq A. Farooqui Index 595

    10 in stock

    £157.65

  • Mutagenic Impurities

    John Wiley & Sons Inc Mutagenic Impurities

    4 in stock

    Book SynopsisLearn to implement effective control measures for mutagenic impurities in pharmaceutical development InMutagenic Impurities: Strategies for Identification and Control,distinguished chemist Andrew Teasdale deliversa thorough examinationof mutagenic impurities and their impact on the pharmaceutical industry. The book incorporates the adoption of the ICH M7 guideline and focuses on mutagenic impurities from both a toxicological and analytical perspective. The editor has created a primary reference for any professional or studentstudying or working with mutagenic impurities and offers readers a definitive narrative of applicable guidelines and practical, tested solutions. It demonstrates the development of effective control measures, including chapters onthe purge tool for risk assessment. The book incorporates a discussion of N-Nitrosamines which was arguably the largestmutagenic impurityissue ever faced by the pharmaceutical industry, resulting in thTable of ContentsList of Contributors xix Preface xxi Section 1 The Development of Regulatory Guidelines for Mutagenic/Genotoxic Impurities – Overall Process 1 1 Historical Perspective on the Development of the EMEA Guideline and Subsequent ICH M7 Guideline 3Andrew Teasdale 1.1 Introduction 3 1.1.1 CPMP – Position Paper on the Limits of Genotoxic Impurities –2002 4 1.1.1.1 Scope/Introduction 4 1.1.1.2 Toxicological Background 4 1.1.1.3 Pharmaceutical (Quality) Assessment 4 1.1.1.4 Toxicological Assessment 4 1.1.2 Guideline on the Limits of Genotoxic Impurities – Draft June 2004 5 1.1.3 PhRMA (Mueller) White Paper 6 1.1.4 Finalized EMA Guideline on the Limits of Genotoxic Impurities – June 2006 8 1.1.4.1 Issues Associated with Implementation 9 1.1.4.2 Control Expectations for Excipients 11 1.1.4.3 Control Expectations for Natural/Herbal Products 12 1.1.4.4 Identification of Potential Impurities 12 1.1.4.5 The Principle of Avoidance 12 1.1.4.6 The ALARP Principle 14 1.1.4.7 Overall 14 1.1.5 SWP Q&A Document 14 1.1.5.1 The Application of the Guideline in the Investigational Phase and Acceptable Limits for GIs Where Applied to Studies of Limited Duration 14 1.1.5.2 Application of the Guideline to Existing Products 15 1.1.5.3 Avoidance and ALARP 17 1.1.5.4 ICH Identification Threshold and its Relation to MI Assessment 17 1.1.6 FDA Draft Guideline 17 1.1.7 Other Relevant Guidance 17 1.1.7.1 Excipients 18 1.1.8 Herbals 18 1.1.9 ICH S9 18 1.1.10 Conclusions 19 References 19 2 ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 21Andrew Teasdale and Raphael Nudelman 2.1 Introduction 21 2.2 ICH M7 22 2.2.1 Introduction 22 2.2.2 Scope 22 2.2.2.1 Established Products 22 2.2.2.2 Anticancer Treatments 23 2.2.2.3 Nature of Therapeutic Agent/Excipients 23 2.2.3 General Principles 24 2.2.4 Considerations for Marketed Products 25 2.2.4.1 Post-approval Changes to Drug Substance, Chemistry, and Manufacturing Controls 26 2.2.4.2 Post-approval Changes to Drug Product Chemistry, Manufacturing, and Controls 26 2.2.4.3 Changes to the Clinical Use of Drug Products 26 2.2.5 Other Considerations for Marketed Products 27 2.2.6 Drug Substance and Drug Product Impurity Assessment 27 2.2.6.1 Synthetic Impurities 28 2.2.6.2 Degradation Products 28 2.2.7 Hazard Assessment 29 2.2.8 Risk Characterization 32 2.2.8.1 Acceptable Intakes Based on Compound-specific Risk Assessments 32 2.2.8.2 Acceptable Intakes for Class 2 and Class 3 Compounds 33 2.2.8.3 Multiple Impurities 34 2.2.8.4 Exceptions and Flexibility in Approaches 35 2.2.9 Control Strategy 35 2.2.9.1 Considerations for Control Approaches 37 2.2.9.2 Considerations for Periodic Testing 37 2.2.9.3 Control of Degradation Products 38 2.2.10 Lifecycle Management 38 2.2.11 Documentation 38 2.2.11.1 Clinical Trail Applications 38 2.2.11.2 Common Technical Document (Marketing Application) 39 2.2.12 Other Aspects 39 2.2.12.1 Relationship Between ICH M7 and ICH Q3A 39 2.3 Conclusions 40 2.4 Commentary on ICH M7 Questions and Answers 40 2.4.1 Section 1 – Introduction 41 2.4.1.1 Question 1.1 41 2.4.1.2 Question 1.2 42 2.4.1.3 Question 1.3 42 2.4.1.4 Question 1.4 42 2.4.2 Section 2 – Scope 43 2.4.2.1 Question 2.1 43 2.4.3 Section 3 – General Principles 43 2.4.3.1 Question 3.1 44 2.4.3.2 Question 3.2 44 2.4.4 Section 4 – Considerations for Marketed Products 44 2.4.4.1 Question 4.1 45 2.4.5 Section 5 – Drug Substance and Drug Product Impurity Assessment 45 2.4.6 Section 6 – Hazard Assessment Elements 45 2.4.6.1 Question 6.1 45 2.4.6.2 Question 6.2 46 2.4.6.3 Question 6.3 47 2.4.6.4 Question 6.4 48 2.4.7 Section 7 – Risk Characterization 48 2.4.7.1 Question 7.1 48 2.4.7.2 Question 7.2 49 2.4.7.3 Question 7.3 49 2.4.7.4 Question 7.4 50 2.4.7.5 Question 7.5 51 2.4.8 Section 9 – Documentation 53 References 55 3 Control Strategies for Mutagenic Impurities 57Andrew Teasdale, Michael Burns, and Michael Urquhart 3.1 Introduction 57 3.2 Assessment Process 58 3.2.1 General 58 3.2.2 Step 1 – Evaluation of Drug Substance and Drug Product Processes for Sources of Potentially Mutagenic Impurities 60 3.2.3 Step 2 – Structural Assessment 61 3.2.4 Step 3 – Classification 61 3.2.5 Step 4 – Assessment of Risk of Potential Carryover of Impurities 63 3.2.6 Overall Quantification of Risk 63 3.2.6.1 Predicted Purge Factor 64 3.2.6.2 Required Purge Factor 65 3.2.6.3 Purge Ratio 66 3.2.6.4 High Predicted Purge 67 3.2.6.5 Moderate Predicted Purge 67 3.2.6.6 Low Predicted Purge 67 3.2.6.7 ICH M7 Control Option 1, 2, or 3 67 3.2.6.8 Step 5 – Further Evaluation 67 3.2.6.9 Safety Testing 67 3.2.7 Quantification of Level Present 68 3.3 Step 6 – Overall Risk Assessment 69 3.4 Further Evaluation of Risk – Purge (Spiking) Studies 70 3.5 Conclusion 70 3.6 Case Studies 71 3.6.1 Case Study 1 – GW641597X 71 3.6.1.1 Ethyl Bromoisobutyrate 2 73 3.6.1.2 Hydroxylamine 74 3.6.1.3 Alkyl Chloride 8 75 3.6.1.4 Additional Evidence for the Purging of Ethyl Bromoisobutyrate and Alkyl Chloride 8 76 3.6.2 Proposed ICH M7-aligned Potential Mutagenic Control Regulatory Discussion 78 3.6.3 Case Study 2 – Candesartan 78 References 84 Section 2 In Silico Assessment of Mutagenicity 87 4 Use of Structure–Activity Relationship (SAR) Evaluation as a Critical Tool in the Evaluation of the Genotoxic Potential of Impurities 89Catrin Hasselgren and Glenn Myatt 4.1 Introduction 89 4.2 (Q)SAR Assessment 90 4.2.1 Looking-up Experimental Data 90 4.2.2 (Q)SAR Methodologies 91 4.2.2.1 Overview 91 4.2.2.2 OECD Validation Principles 91 4.2.3 Expert Rule-Based Methodology 92 4.2.4 Statistical-Based Methodology 95 4.2.5 Applying (Q)SAR Models 97 4.2.6 Expert Review 98 4.2.6.1 Overview 98 4.2.6.2 Refuting a Statistical-Based Prediction 100 4.2.6.3 Mechanistic Assessment 101 4.2.6.4 Assessing Lack of Chemical Reactivity 101 4.2.7 Class Assignment 103 4.2.7.1 Overview 103 4.2.8 Documentation 109 4.3 Discussion 109 4.4 Conclusions 110 Acknowledgments 111 References 111 5 Evolution of Quantitative Structure–Activity Relationships ((Q)SAR) for Mutagenicity 115James Harvey and David Elder 5.1 Introduction 115 5.2 Pre ICH M7 Guideline 116 5.3 Post ICH M7 117 5.3.1 Evolution of (Q)SAR Platforms 117 5.3.2 Robust Negative In Silico (Q)SAR Predictions 118 5.3.3 Development of Composite (Q)SAR Models 119 5.3.4 Expansion of Training Data Sets to Enhance the Predictive Power of (Q)SAR Tools 120 5.3.5 Focused Data Sharing Initiatives on Specific Chemical Classes 120 5.3.5.1 Understanding In Vitro Mechanisms Leading to Mutagenicity 121 5.3.5.2 Shared Data, Shared Progress 122 5.3.6 Novel Data Mining Approaches 125 5.3.6.1 Case Study: Primary Aromatic Amines (PAAs) 125 5.3.6.2 Case Study: Aromatic N-oxides 125 5.4 Expert Knowledge 127 5.5 Future Direction 129 References 131 Section 3 Toxicological Perspective on Mutagenic Impurities 137 6 Toxicity Testing to Understand the Mutagenicity of Pharmaceutical Impurities 139Andrew Teasdale, John Nicolette, Joel P. Bercu, James Harvey, Stephen Dertinger, Michael O’Donovan, and Christine Mee 6.1 Introduction 139 6.2 In Vitro Genotoxicity Tests 141 6.2.1 Background 141 6.2.2 Bacterial Reverse Mutation or “Ames” Test 142 6.2.3 Modifications to the Standard Ames Test 145 6.2.3.1 Six-well Ames Assay 146 6.2.4 Test Strategy 146 6.3 In Vivo Mutation Assays 148 6.3.1 In Vivo Pig-a Gene Mutation Assay 148 6.3.2 Rodent Micronucleus Test 152 6.3.3 Rodent “Comet” Assay 155 6.3.4 Transgenic Rodent (TGR) Mutation Assay 155 6.4 Conclusions 158 Glossary 159 References 160 7 Compound-and Class-Specific Limits for Common Impurities in Pharmaceuticals 165Joel P. Bercu, Melisa J. Masuda-Herrera, Alejandra Trejo-Martin, David J. Snodin, Kevin P. Cross, George E. Johnson, James Harvey, Robert S. Foster, David J. Ponting, and Richard V. Williams 7.1 Introduction 165 7.2 Monograph Development 167 7.2.1 Exposure to the General Population 167 7.2.2 Mutagenicity/Genotoxicity 170 7.2.3 Noncarcinogenic Effects 170 7.2.4 Carcinogenic Effects 170 7.2.5 Mode of Action (MOA) and Assessment of Human Relevance 171 7.2.6 Toxicokinetics 171 7.2.7 Regulatory/Published Limits 171 7.3 Derivation of the Compound-specific Limit 171 7.3.1 PoD Selection 172 7.3.2 Limited Data Sets 172 7.3.3 PDE Development 172 7.3.4 AI Development 172 7.3.5 Class-specific Limit 173 7.3.6 Less than Lifetime (LTL) AIs 173 7.4 Examples of Published Compound-specific Limits 173 7.4.1 Mutagenic Carcinogens 173 7.4.2 Nonmutagenic Carcinogens 176 7.4.3 Mutagenic Noncarcinogens 176 7.4.4 Nonmutagenic Compounds 176 7.4.5 Mutagenic In vitro but not In vivo 176 7.4.6 Route of Administration-specific Limits 177 7.5 Class-specific Limits 177 7.5.1 Alkyl Chlorides 177 7.5.2 Alkyl Bromides 178 7.5.3 N-Nitrosamines 178 7.5.3.1 Regulatory Limits for N-Nitrosamines 178 7.5.3.2 Additional Proposed Limits for N-Nitrosamines 180 7.5.3.3 N-Nitrosamine Exposure in the General Population 181 7.5.3.4 Developing a Class-specific Limit for N-Nitrosamines 182 7.5.4 Arylboronic Acids and Esters 193 7.6 EMS Case Study and Updated Toxicity Analysis 196 7.6.1 Potential for Human Exposure 196 7.6.2 Mutagenicity/Genotoxicity 196 7.6.3 Noncarcinogenic Effects 198 7.6.4 Carcinogenicity 199 7.6.5 Regulatory and/or Published Limits 199 7.6.6 Permitted Daily Exposure 199 7.7 Extractables and Leachables 202 7.8 Lhasa AI/PDE Database for Impurities 203 7.9 Conclusions and Future Directions 203 Acknowledgments 204 References 204 8 Genotoxic Threshold Mechanisms and Points of Departure 213George E. Johnson, Shareen H. Doak, Gareth J.S. Jenkins, and Adam D. Thomas 8.1 Introduction to Genotoxic Dose Responses 213 8.1.1 The Linear Default Position for Genotoxic Carcinogens 213 8.1.2 Theoretical Evidence for Rejecting the Linear Approach 214 8.1.3 In Vitro Experimental Evidence for Threshold Mechanism 215 8.1.4 In Vivo Evidence for Genotoxic Thresholds 218 8.2 Threshold Mechanisms 221 8.2.1 Statistical Assessment of Dose Response Data Sets 224 8.2.2 Extrapolation from One Chemical to Another 224 8.2.3 Extrapolation of Threshold Mechanisms and PoDs to Populations 225 8.3 Conclusions 227 References 227 Section 4 Quality Perspective on Genotoxic Impurities 233 9 Mutagenic Impurities – Assessment of Fate and Control Options 235Michael W. Urquhart, Andrew Teasdale, and Michael Burns 9.1 Introduction/Background 235 9.2 Reactivity 236 9.2.1 Reactivity Classification 238 9.3 Solubility – Isolated Stages 238 9.4 Recrystallization 239 9.4.1 Solubility – Liquid/Liquid Partitioning 239 9.5 Volatility 241 9.6 Chromatography 241 9.7 Other Techniques 242 9.7.1 Activated Charcoal 242 9.7.2 Scavenger Resins 242 9.8 Overall Quantification of Risk 243 9.9 Alignment to ICH M7 – Control Options 244 9.10 Control Option Selection 247 9.10.1 Predicted Purge Factor 248 9.10.2 Required Purge Factor 249 9.10.3 Purge Ratio 249 9.10.4 High Predicted Purge 250 9.10.5 Moderate Predicted Purge 250 9.10.6 Low Predicted Purge 250 9.10.7 ICH M7 Control Option 1, 2, or 3 251 9.10.8 Representative Data to be Supplied in Regulatory Submission Under an ICH M7 Control Strategy 251 9.10.9 Summary of PMI Purging Across the Synthetic Route 251 9.10.10 Details of Individual Impurity Purging Through the Subsequent Downstream Chemistry 253 9.10.11 Development of a Knowledge Base Expert In Silico System 254 9.10.12 Experimental Work to Assess Reactivity 257 9.11 Utilizing Mirabilis for a Purge Calculation 259 9.11.1 Utility of In Silico Predictions 260 9.11.1.1 Case Study – Camicinal [38] 260 References 266 10 N-Nitrosamines 269Andrew Teasdale, Justin Moser, J. Gair Ford, and Jason Creasey 10.1 Background 269 10.2 Generation of N-Nitrosamines 270 10.3 Article 31 273 10.4 Further Issues – Cross Contamination and Ranitidine 275 10.4.1 Article 5(3) and Associated Q&A Document 276 10.5 How to Assess the Risk Posed in Pharmaceuticals 278 10.5.1 Drug Substance 278 10.5.1.1 Where do Nitrites Come Within Drug Substance Come From? 278 10.5.1.2 What Other Sources Are There? 278 10.5.1.3 Other Factors Associated with Drug Substance Synthesis 280 10.5.2 Process to Assess Drug Substance-Related Risk 280 10.5.3 Drug Product-Related Risk 282 10.5.3.1 Related Risks of Contamination and Formation in Drug Products 282 10.5.4 Container Closure Systems 289 10.5.5 Elastomeric Components 291 10.5.6 Nitrosamine Impurities in Biologics 293 10.5.6.1 Active Substance 293 10.5.6.2 The Water Used in Formulation Is Depleted in Nitrosating Agents 295 10.5.6.3 Bioconjugated or Chemically Modified Products 295 10.5.6.4 Excipients 296 10.6 Regulatory Guidance Pursuant to N-Nitrosamines and its Implications 297 10.6.1 Article 31 Process and Outcomes 297 10.6.1.1 Article 31 Request 297 10.6.2 Sartans Lessons Learnt Report 298 10.6.2.1 Reflection on the Initial Section of the EMA Report 299 10.6.3 Article 5(3) Report 299 10.6.3.1 Quality 299 10.6.3.2 Consideration for Analytical Method Development to Identify and Quantify N-Nitrosamines in Drug Substances and Medicinal Products 300 10.6.3.3 Safety 301 10.6.3.4 Conclusions 305 10.6.4 EMA Question and Answer Document [6] 305 10.6.4.1 Further Revision of the EMA Question and Answer Document 310 10.6.5 FDA Guideline 310 10.6.5.1 Introduction and Background 310 10.6.5.2 Recommendations 310 10.6.5.3 Acceptable Intakes (section III.A) 313 10.6.5.4 Quality/Chemistry and Controls 314 10.7 Way Forward 315 Acknowledgments 316 References 317 11 Conditions Potentially Leading to the Formation of Mutagenic Impurities 321Lucie Lovelle, Andrew Teasdale, Ian Ashworth, Adrian Clarke, and Alan Steven 11.1 Problematic Reagent Combinations per Structural Alert 323 11.1.1 N-Nitroso Compounds (COC) 323 11.1.1.1 Amines and Nitrosating Agents [10] 323 11.1.1.2 Amine Derivatives and Nitrosating Agents 324 11.1.1.3 Other 324 11.1.2 Alkyl-azoxy Compounds (COC) 325 11.1.2.1 Reduction [52–54] 325 11.1.2.2 Oxidation 325 11.1.2.3 Others 325 11.1.3 Other N-O Compounds 326 11.1.3.1 Reduction of Nitro Groups 326 11.1.3.2 Oxidation of Amines and Hydroxylamines 326 11.1.4 Nitration 326 11.1.5 Other N-N Compounds [59, 60] 326 11.1.6 Aflatoxin-like Compounds [62] (COC) 327 11.1.7 Dioxin-like Compounds (Including Polychlorinated Biphenyls = PCBs) [63] 327 11.1.8 Alkyl and Acyl Halides 327 11.1.8.1 ROH + HCl → RCl + H2O 327 11.1.8.2 Ether Opening with Halides 328 11.1.9 Methyl Sulfoxides and Pummerer Rearrangement 328 11.1.10 Acyl Chlorides Formation [82] 329 11.1.11 Halogenation of Unsaturated Compounds 329 11.1.12 Ammonium Salts (Hofmann Elimination) 329 11.1.12.1 Alkyl Sulfonates [90] 329 11.1.13 Epoxides and Aziridines [95–97] 330 11.2 Miscellaneous 331 11.2.1 B and P Based Compounds 331 11.2.2 Formation of N-Methylol 331 11.2.3 Acetamide 332 11.2.4 Quinones and Quinone Derivatives 332 11.2.5 Anilines [100] 332 11.2.6 Michael Acceptors 333 11.2.7 Others 333 11.3 Mechanism and Processing Factors Affecting the Formation of N-nitrosamines 333 11.3.1 Introduction 333 11.3.2 Mechanisms of Amine Nitrosation 333 11.3.2.1 Nitrosation of Secondary Amines 333 11.3.2.2 Aqueous Nitrosation 334 11.3.2.3 Nitrosation in Organic Solvents 336 11.3.3 Nitrosation of Tertiary Amines 337 11.3.3.1 Nitrosation of Quaternary Amines 337 11.3.3.2 Nitrosation of Amine Oxides 338 11.3.4 Sources of Nitrosating Agents 338 11.3.4.1 Process Water 338 11.3.4.2 Nitric Acid 339 11.3.4.3 Atmospheric Sources 339 11.3.4.4 Excipients Used in Drug Product Manufacture 340 11.3.4.5 Nitrocellulose 340 11.3.4.6 Nitrosating Agent Scavengers 340 11.3.4.7 Removal of Nitrosamines 341 11.4 Formation, Fate, and Purge of Impurities Arising from the Hydrogenation of Nitroarenes to Anilines 341 11.4.1 Primary Reaction Mechanism 341 11.4.2 Mass and Heat Transfer Effects 342 11.4.3 Condensation Chemistry 344 11.4.4 Factors Affecting Aryl Hydroxylamine Accumulation 346 11.4.5 Aryl Hydroxylamine Control 347 11.4.5.1 Use of Cocatalysts 347 11.4.5.2 Physical Adsorption 348 11.4.5.3 Kinetic Understanding Around Formation and Consumption 349 11.4.5.4 Holistic Control of Impurity Profile 349 11.4.6 Controlling Residual Nitroarene 351 11.4.7 Specific Considerations of Alkyl Nitro Reductions 353 11.4.8 Closing Comments on Hydrogenation of Nitroarenes to Anilines 353 11.5 Mechanism and Processing Parameters Affecting the Formation of Sulfonate Esters – Summary of the PQRI Studies 353 11.5.1 Introduction 353 11.5.2 Reaction Mechanism 355 11.5.3 Experimental Results 357 11.5.3.1 Experimental Results from Study of the Ethyl Methanesulfonate (EMS) System 357 11.5.3.2 Other Methanesulfonic Acid Systems 359 11.5.3.3 Experimental Results from Study of the Isopropyl Methanesulfonate (IMS) System 360 11.5.4 Experimental Results from Study of Toluenesulfonic (Tosic) Acid Systems 361 11.5.4.1 Experimental Results from Study of the Ethyl Tosylate (ETS) System 362 11.5.4.2 Kinetic Modeling 363 11.5.4.3 Key Learnings and Their Implications for Process Design 365 11.5.4.4 Processing Rules 366 11.5.5 What About Viracept™? 366 11.5.6 What About Other Sources of Sulfonate Esters? 367 11.5.7 Potential for Ester Formation in the Solid Phase 368 11.5.8 Conclusions 369 References 369 12 Strategic Approaches to the Chromatographic Analysis of Mutagenic Impurities 381Frank David, Gerd Vanhoenacker, Koen Sandra, Pat Sandra, Tony Bristow, and Mark Harrison 12.1 Introduction 381 12.2 Method Development and Validation 384 12.3 Analytical Equipment for Mutagenic Impurity Analysis 385 12.4 Alkyl Halides and Aryl Halides 388 12.4.1 Method Selection 388 12.4.2 Typical Conditions Used for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 390 12.4.2.1 Sample Preparation 390 12.4.2.2 GC-MS Parameters 391 12.4.3 Typical Results Obtained for Alkyl-and Aryl Halide Analysis by SHS-GC-MS and SPME-GC-MS 391 12.5 Sulfonates 393 12.5.1 Method Selection 393 12.5.2 Typical Conditions Used for Sulfonate Analysis by Derivatization SHS-GC-MS 394 12.5.2.1 Sample Preparation 395 12.5.2.2 Synthesis of Deuterated Internal Standards 395 12.5.2.3 GC-MS Parameters 395 12.5.3 Typical Results Obtained Using Derivatization – SHS – GC-MS 395 12.5.4 Confirmation Analysis by PTV-GC-MS 396 12.6 S-and N-mustards 398 12.6.1 Method Selection 398 12.6.2 Typical Analytical Conditions for the Analysis of N-mustards by Derivatization – SPME-GC-MS 399 12.6.2.1 Sample Preparation 399 12.6.3 Typical Results for N-mustards by Derivatization – SPME-GC-MS 399 12.7 Michael Reaction Acceptors 400 12.7.1 Method Selection 400 12.7.2 Typical Analytical Conditions for Michael Reaction Acceptors 400 12.7.2.1 Sample Preparation 401 12.7.2.2 Parameters for SHS-GC-MS 401 12.7.2.3 Parameters for Liquid Injection and GC-MS with Back-flush 402 12.7.3 Typical Results Obtained for Trace Analysis of Michael Reaction Acceptors 402 12.7.3.1 SHS with PTV 402 12.7.3.2 Liquid Injection GC-MS 403 12.8 Epoxides 404 12.8.1 Method Selection 404 12.8.2 Typical Analytical Conditions for the Analysis of Volatile Epoxides by SHS-GC-MS 406 12.8.2.1 Sample Preparation 406 12.8.2.2 SHS-GC-MS Parameters 406 12.8.3 Typical Results Obtained for Volatile Epoxides Using SHS-GC-MS 407 12.9 Haloalcohols 407 12.9.1 Method Selection 407 12.9.2 Analytical Conditions for Trace Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 409 12.9.2.1 Sample Preparation 409 12.9.2.2 2D-GC-MS Parameters 410 12.9.3 Typical Results for Analysis of Halo-alcohols by Derivatization and Liquid Injection - 2DGC-MS 410 12.10 Aziridines 411 12.10.1 Method Selection 411 12.10.2 Typical Analytical Conditions for RPLC-MS and HILIC-MS Analysis of Aziridines 412 12.10.2.1 Sample Preparation 412 12.10.2.2 RPLC-MS Method Parameters 413 12.10.2.3 HILIC-MS Method Parameters 413 12.10.3 Typical Results Obtained for Aziridine Analysis Using RPLC and HILIC 413 12.11 Arylamines and Amino Pyridines 414 12.11.1 Method Selection 414 12.11.2 Typical Analytical Conditions for Arylamines and Aminopyridines by RPLC-MSD 415 12.11.2.1 Sample Preparation 415 12.11.2.2 HPLC-MS Parameters 416 12.11.3 Typical Results for Arylamines and Aminopyridines by RPLC-MSD 417 12.12 Hydrazines and Hydroxylamine 419 12.12.1 Method Selection 419 12.12.2 Analytical Conditions for the Analysis of Hydrazines Using Derivatization and HPLC-MS 420 12.12.2.1 Sample Preparation 421 12.12.2.2 HPLC-MS Parameters 421 12.12.3 Typical Results Obtained for Hydrazines Using Derivatization LC-MS 421 12.13 Aldehydes and Ketones 423 12.13.1 Method Selection 423 12.13.2 Typical Analytical Conditions for Analysis of Aldehydes and Ketones by DNPH Derivatization, Followed by LC-MS Analysis 423 12.13.2.1 Sample Preparation 424 12.13.2.2 Derivatization Reagent Solution 425 12.13.2.3 HPLC-MS Parameters 425 12.13.3 Typical Results Obtained for Aldehyde Analysis by DNPH Derivatization – LC-MS 426 12.14 Nitrosamines 426 12.14.1 Method Selection 426 12.14.2 Sample preparation for SHS-GC-MS Analysis (according to ref [85]) 428 12.14.2.1 SHS-GC-MS Analysis [85] Sample Preparation 428 12.14.2.2 GC-MS (HRAM-MS) Conditions 428 12.14.2.3 UHPLC-MS Analysis 429 12.14.2.4 Sample Preparation for Hydrophilic Samples (e.g. Metformin) 429 12.14.2.5 Sample Preparation for Hydrophobic Matrices 430 12.14.2.6 UHPLC Conditions 430 12.14.2.7 HRAM-MS and MS/MS Conditions 430 12.14.3 Typical Results Obtained for Volatile N-nitrosamines Using SHS-GC-MS 430 12.14.4 Typical Results Obtained for N-nitrosamines Using LC-MS 431 12.15 Nontarget Analysis of PMI/MIs 434 12.16 Conclusions 435 Acknowledgements 436 References 436 13 Analysis of Mutagenic Impurities by Nuclear Magnetic Resonance (NMR) Spectroscopy 439Andrew R. Phillips and Stephen Coombes 13.1 Introduction to NMR 439 13.2 Why Is NMR an Insensitive Technique? 439 13.2.1 Nuclear Spin 439 13.2.2 Boltzmann Distribution 440 13.3 How Could NMR Be Used for Trace Analysis? 440 13.3.1 Generating an NMR Spectrum 440 13.3.2 Chemical Shift 442 13.3.3 Scalar Coupling 443 13.3.4 The Quantitative Nature of NMR 444 13.3.5 Relaxation 445 13.3.6 Summary 446 13.4 What Can Be Done to Maximize Sensitivity? 446 13.4.1 System Performance 447 13.4.1.1 Field Strength 447 13.4.2 Probe Performance 447 13.4.2.1 Probe Design 447 13.4.2.2 Probe Diameter 448 13.4.2.3 Cryogenically Cooled Probes 448 13.4.3 Substrate Concentration 449 13.4.4 Molecular Weight Ratio 451 13.4.5 Acquisition Time and Signal Averaging 451 13.4.6 Number of Protons and Linewidth 453 13.4.7 Resolution 455 13.4.8 Dynamic Range 455 13.4.8.1 Selective Excitation 458 13.4.8.2 Shaped Pulses 458 13.4.8.3 Quantification Using Selective Pulses 460 13.4.8.4 Excitation Sculpting 461 13.4.9 Limit Tests 461 13.4.9.1 Method Development 462 13.4.9.2 Validation 463 13.4.9.3 Unresolved Signals 463 13.4.9.4 Rapid Analysis 464 13.4.10 Expanded Use of MI NMR Methodology 464 13.4.11 Summary 464 13.5 Case Studies 464 13.5.1 Case Study 1 – An Aldehyde Functionalized MI 464 13.5.2 Case Study 2 – Use of 19F NMR 466 13.5.3 Case Study 3 – Epoxide and Chlorohydrin MIs 468 13.5.4 Case Study 4 – Sulfonate Esters 469 13.5.5 Case Study 5 – Limit Test for Poorly Resolved Signals 470 13.5.6 Case Study 6 – Using NMR MI Methodology for Cleaning Validation 472 13.6 Conclusion 473 References 475 14 Addressing the Complex Problem of Degradation-Derived Mutagenic Impurities in Drug Substances and Products 477Steven W. Baertschi and Andrew Teasdale 14.1 Introduction 477 14.1.1 Background 477 14.2 Working Definitions 478 14.3 Challenges Associated with the Assessment of Risk Posed by (Potentially) Mutagenic Degradation Products 479 14.4 Risk Assessment Process for Mutagenic Degradants 479 14.4.1 Stability-Related MRA Process Overview 479 14.4.2 Stress Studies 480 14.4.3 Accelerated Stability Studies 480 14.4.4 Long-term ICH Stability Studies 481 14.4.5 Deciding Which Products to Include in the MRA 481 14.4.6 In Silico Tools for the Prediction of Potential Degradation Products 482 14.5 Using Stress Testing to Select Degradation Products for Identification 482 14.5.1 Approach 1: Criteria for Structure Identification After Observation in Accelerated and Long-term Stability Studies 483 14.5.2 Approach 2: Criteria for Structure Identification Through Use of an Algorithm in Stress Testing Studies 483 14.5.3 Approach 3: Structure Identification Through Use of Kinetic Equivalence and Scaled ICH Q3B Thresholds 485 14.5.3.1 Kinetic Equivalence 485 14.5.3.2 Scaled ICH Q3B Thresholds 486 14.6 Development Timeline Considerations 487 14.6.1 Drug Discovery Stage 487 14.6.2 Preclinical to Phases 1/2 487 14.6.3 Phase 3 to New Drug Application (NDA) Regulatory Submission 488 14.6.4 Post-marketing/Line Extensions 488 14.7 Developing Control Strategies for (Potential) Mutagenic Degradation Products 488 14.7.1 Determining Relevancy of Potential Degradation Products and Developing Control Strategies for Actual Degradation Products 488 14.7.2 Accelerated Stability (40 °C/75% RH Six months) or Kinetic Equivalent 489 14.7.3 Photostability Studies 489 14.7.4 Degradation Chemistry Knowledge 490 14.8 Risk Assessment Process Illustrated 491 14.8.1 Case Study #1: Molecule A 491 14.8.2 Case Study #2: Galunisertib 492 14.8.3 Case Study #3: Naloxegol 494 14.8.4 Case Study #4: Selumetinib Side Chain 496 14.9 Significance of the Risk of Forming Mutagenic Degradation Products 498 14.9.1 Frequency of Alerting Structures in Degradation Products 498 14.10 Degradation Reactions Leading to Alerting Structures in Degradation Products 499 14.10.1 Frequency of Alerting Structures Giving Rise to Ames Positive Tests 503 14.10.2 Mutagenic Degradation Products: Overall Predicted Frequency 503 14.11 N-Nitrosamines: Special Considerations 503 14.11.1 Evaluation of Potential Formation of N-Nitrosamines in Drug Product 504 14.12 Conclusions 506 References 507 Index 513

    4 in stock

    £168.26

  • Clinical Pharmacology and Therapeutics

    John Wiley and Sons Ltd Clinical Pharmacology and Therapeutics

    Out of stock

    Book SynopsisTable of ContentsPreface vi Contributors vii Part 1 Principles of clinical pharmacology 1 Pharmacodynamics and pharmacokinetics 3 2 Clinical trials and drug development 29 3 Pharmacoeconomics: the economic evaluation of new drugs 35 4 Practical prescribing 42 Part 2 Aspects of prescribing 5 Gastrointestinal system 51 6 Cardiovascular system: Management of coronary artery disease and its complications 63 7 Respiratory system 102 8 Nervous system 113 9 Infection 142 10 Drugs and endocrine disease 175 11 Genitourinary system 196 12 Malignant disease 211 13 Drugs and the blood 221 14 Musculoskeletal system 236 15 Immunopharmacology 242 16 Travel medicine 255 17 Analgesia and anaesthesia 266 18 Poisoning and drug overdose 281 Index 295

    Out of stock

    £32.25

  • Neglected Tropical Diseases and Phytochemicals in

    John Wiley & Sons Inc Neglected Tropical Diseases and Phytochemicals in

    Out of stock

    Book SynopsisNEGLECTED TROPICAL DISEASES AND PHYTOCHEMICALS IN DRUG DISCOVERY Explore novel drug discovery updates from medicinal plants to help fight the devastating effects of neglected tropical diseases Neglected Tropical Diseases and Phytochemicals in Drug Discovery delivers a comprehensive exploration of the drug discovery process as it pertains to neglected tropical diseases. The book covers recent advancements in drug discovery, as well as druggable targets and new challenges facing the industry. It offers readers expansive discussions of specific diseases, including protozoan, helminth, bacterial, viral, fungal, and ectoparasitic infections. This book provides readers with insightful perspectives from leading industry voices on fifty years of trends and progress in the search for new, safe, and affordable therapeutic drugs in the fight against neglected tropical diseases. It includes information beneficial to researchers in a variety of fields of biology, chemistry, medicine, and pharmaceutTable of ContentsList of Contributors xxi Preface xxvii Part I Introduction to Neglected Tropical Diseases 1 1 Epidemiology of Neglected Tropical Diseases 3 Kurubaran Ganasegeran and Surajudeen Abiola Abdulrahman 2 Neglected Tropical Diseases, Phytochemicals, Protein Targets,and Mechanisms in Drug Discovery 37 Lalit R. Samant, Tehseen M. Dhorajiwala, and Sumit T. Haldar 3 Novel Bioactive Lead Compounds for Drug Discovery Against NeglectedTropical Diseases, Leishmaniasis, Lymphatic Filariasis, Trypanosomiasis(African Sleeping Sickness and Chagas Disease), and Schistosomiasis 75 Abeer M. El Sayed and Chukwuebuka Egbuna Part II Protozoan Infections 135 4 Herbal, Nutritional, and Traditional Remedies for Giardiasis:Phytochemicals as Drug Candidates 137 Samrat Bhattacharyya 5 Antiprotozoal Activity of Phytochemicals Against Entamoeba histolytica, the Causative Agent of Amoebiasis 171 Goutam Kumar Jena, Chinam Niranjan Patra, and Jnyanaranjan Panda 6 Antileishmanial Potentials of Phytochemicals 183 Shahira M. Ezzat, Mohamed A. Salem, and Ahmed Zayed Part III Helminth Infections 199 7 Prospects of Phytochemicals for the Treatment of Helminthiasis 201 Muhammad Akram, Charles Oluwaseun Adetunji, Ejaz Mohiuddin, Tolulope Olawumi Oladosun, Phebean Ozolua, Frances N. Olisaka, Chukwuebuka Egbuna, Olugbenga Samuel Micheal, Juliana Bunmi Adetunji, Leena Hameed, Chinaza Godswill Awuchi, Kingsley C. Patrick-Iwuanyanwu, and Olugbemi Tope Olaniyan 8 Efficacy of Phytochemicals of Medicinal Plants for the Treatment of Human Echinococcosis: Echinococcal Disease, Hydatidosis, or Hydatid Disease Drug Discovery 225 Charles Oluwaseun Adetunji, Chukwuebuka Egbuna, Tolulope Olawumi Oladosun, Muhammad Akram, Olugbenga Samuel Micheal, Frances N. Olisaka, Phebean Ozolua, Juliana Bunmi Adetunji, Goddidit Esiro Enoyoze, and Olugbemi Tope Olaniyan 9 Filaricidal Activity of Phytochemicals Against Lymphatic Filariasis 245 Jayashree V. Hanchinalmath, Darcia D’mello, Kirankumar Shivasharanappa, T. Pramod, and Sharangouda J. Patil 10 Dracunculiasis (Guinea Worm Disease) and Phytochemicals in Drug Discovery 271 Muhammad Akram, Chukwuebuka Egbuna, Mehwish Iqbal, Zarrin Basharat, Mithun Rudrapal, Kingsley C. Patrick-Iwuanyanwu, Johra Khan, and Chukwuemelie Zedech Uche 11 Medicinal Potentials of Phytochemicals as a Source of Drugs for the Treatment of Onchocerciasis (River Blindness) 283 Chandrashekar Srinivasa, Chandan Shivamallu, S. R. Santhosh Kumar, P. Sushma, Shiva Prasad Kollur, Seema J. Patel, S. S. Patil, R. Suhas, Chukwuebuka Egbuna, and Bui Thanh Tung 12 Foodborne Trematodiases and Phytochemicals 299 Shashank M. Patil, Ramith Ramu, Prithvi S. Shirahatti, and K. Sumana Part IV Bacterial Infections 337 13 Bacteriocidal Effects of Phytochemicals on Mycobacterium ulcerans, the Causative Agents of Buruli Ulcer 339 Alloysius Chibuike Ogodo, Francis Ushie Ebuara, and Chidera Favour Ogodo 14 Bactericidal Effects of Phytochemicals on Mycobacterium leprae, the Causative Agent of Leprosy 359 Chukwuebuka Egbuna, Muhammad Akram, Surajudeen Abiola Abdulrahman, Andrew G. Mtewa, Mithun Rudrapal, Kingsley C. Patrick-Iwuanyanwu, Saher Rahat, Iram Ghaffar, Amna Siddique, Jonathan Chinenye Ifemeje, Michael C. Olisah, Mihnea-Alexandru Ga˘man, Bui Thanh Tung, Chandan Shivamallu, Chukwuemelie Zedech Uche, and Johra Khan 15 Medicinal Plants and Phytochemicals Effective Against Chlamydia trachomatis, the Causative Agent of Trachoma 381 Yusuf Abubakar, Chukwuebuka Egbuna, Ahmed Olatunde, Habibu Tijjani, and Uchenna Estella Odoh 16 Yaws (Endemic Treponematoses) Drug Discovery from Phytochemicals: An Informatics Protocol for Drug Target Identification to Phytochemical Inhibitor Screening and Validation 397 Zarrin Basharat and Arisha Khoso Part V Viral Infections 417 17 Dengue Fever: A Brief Overview and Insights into the Potential Applicability of Phytochemicals in Its Management 419 Muhammad Akram, Charles Oluwaseun Adetunji, Chukwuebuka Egbuna, Shaista Jabeen, Olugbemi Tope Olaniyan, Nebechi Jane Ezeofor, Osikemekha Anthony Anani, Umme Laila, Mihnea-Alexandru Ga˘man, Kingsley C. Patrick-Iwuanyanwu, Jonathan Chinenye Ifemeje, Chukwudi Jude Chikwendu, Michael C. Olisah, and Mithun Rudrapal 18 Medicinal Potentials of Phytochemicals for the Management of Rabies 441 D. Chandan, Shiva Prasad Kollur, Shashanka K. Prasad, Chandrashekar Srinivasa, Prabhurajeshwar, S. M. Gopinath, Chukwuebuka Egbuna, and Chandan Shivamallu Part VI Fungal and Ectoparasitic Infections 453 19 Roles of Medicinal Plants in the Diagnosis and Treatment of Eumycetoma 455 Chinaza Godswill Awuchi, Muhammad Akram, and Chibueze Gospel Awuchi 20 Role of Phytochemicals in the Treatment of Ectoparasitic Infections: Scabies and Myiasis 477 Santwana Palai, Shyam Sundar Kesh, Chinaza Godswill Awuchi, Surajudeen Abiola Abdulrahman, and Chukwuebuka Egbuna Part VII Non Classified NTDs: Malaria and Human Tuberculosis 499 21 Malaria and Recent Developments in Antimalarial Drugs 501 Mithun Rudrapal and Dipak Chetia 22 Therapeutic Potentials of Phytochemicals Against Mycobacterium tuberculosis, the Causative Agent of Tuberculosis 543 Alloysius Chibuike Ogodo, Verwiyeh Silas Tatah, Francis Ushie Ebuara, and Chidera Favour Ogodo Index 571

    Out of stock

    £161.06

  • Oral Bioavailability and Drug Delivery

    John Wiley & Sons Inc Oral Bioavailability and Drug Delivery

    2 in stock

    Book SynopsisORAL BIOAVAILABILITY AND DRUG DELIVERY Improve the performance and viability of newly-developed and approved drugs with this crucial guide Bioavailability is the parameter which measures the rate and extent to which a drug reaches a user's circulatory system depending on the method of administration. For example, intravenous administration produces a bioavailability of 100%, since the drugs are injected directly into the circulatory system; in the case of oral administration, however, bioavailability can vary widely based on factors which, if not properly understood, can result in a failure in drug development, adverse effects, and other complications. The mechanics of oral bioavailability are therefore critical aspects of drug development. Oral Bioavailability and Drug Delivery provides a comprehensive coverage of this subject as well as its drug development applications. Beginning with basic terminology and fundamental concepts, it provideTable of ContentsList of Contributors xxix Foreword xxxix Preface xli 1 Barriers to Oral Bioavailability – An Overview 1 Ming Hu and Xiaoling li 1.1 Introduction 1 References 4 2 Solubility of Pharmaceutical Solids 5 Pramila Sharma, Yi Gao, Heran li, Bhaskara R. Jasti, Sanming li, and Xiaoling li 2.1 Introduction 5 2.2 Fundamentals of Solubility 6 2.3 Solubility and Oral Bioavailability 19 2.4 Strategies to Improve Solubility 21 2.5 Summary 24 Abbreviations 25 References 25 3 In Vitro Dissolution of Pharmaceutical Solids 31 Tze Ning Hiew and Paul W.S. Heng 3.1 Dissolution Theory and Fundamentals 31 3.2 Dissolution of Drug Products 34 3.3 In Vitro Dissolution Methods for Ensuring Quality of Commercial Drug Products 36 3.4 In Vitro Dissolution Methods in Product Development 38 3.5 Automation in Dissolution Testing and Prediction 40 3.6 Conclusions 42 References 42 4 Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption 47 Paul C.L. Ho 4.1 Introduction 47 4.2 Biological Features of Gastrointestinal Tract 47 4.3 Physiological Features of Gastrointestinal Tract 51 4.4 Other Physiological Factors 54 4.5 Conclusion 56 References 56 5 Absorption of Drugs Via Passive Diffusion and Carrier-Mediated Pathways 61 Amit Kokate, Jae H. Chang, and Miki S. Park Disclaimer 61 5.1 Introduction 61 5.2 Passive Diffusion 62 5.3 Carrier-Mediated Transport 67 5.4 Summary 75 References 75 6 Determinant Factors for Passive Absorption of Drugs 79 Wei Zhu and Mikolaj Milewski 6.1 Introduction 79 6.2 Fundamentals of Drug Absorption 79 6.3 Absorption Determining Factors 82 6.4 Rate Limiting Steps in Absorption and Prediction of Dosing Amount Absorbed 86 6.5 Overview of In Silico Prediction of Absorption and Pharmacokinetics for Oral Dosage Forms 88 6.6 Summary 89 References 90 7 Protein Binding and Drug Distribution 95 HaiAn Zheng and Marcel Musteata 7.1 Introduction 95 7.2 Protein–Drug Binding in Plasma 95 7.3 Modeling of Binding Equilibria 97 7.4 Bioanalytical Methods for Studying Drug–Protein Binding 98 7.5 Impact of Drug–Protein Binding on Pharmacokinetic Parameters 105 7.6 Physicochemical Factors that Affect Protein–Drug Binding and Drug Distribution 106 7.7 Physiological and Pathological Factors that Affect Protein–Drug Binding and Drug Distribution 107 References 107 8 Drug Transport Across the Placental Barrier 111 Valentina Bryant, Mansi Shah, Jennifer Waltz, and Erik Rytting 8.1 Introduction 111 8.2 Pharmacokinetics of Drugs Administered During Pregnancy 111 8.3 Placental Development and Structure 112 8.4 Functions of the Human Placenta 113 8.5 Mechanisms of Drug Transport Across the Placenta 114 8.6 Mechanisms of Drug Metabolism Within the Placenta 116 8.7 Strategies to Alter Drug Transport Across the Placenta 117 8.8 Experimental Models of the Human Placenta 118 References 122 9 Biopharmaceutics Classification System: Theory and Practice 131 Mehul Mehta, Jayabharathi Vaidyanathan, and Lawrence Yu 9.1 Introduction 131 9.2 Theory 131 9.3 BCS-based Biowaiver 134 9.4 BCS Waiver Case Studies 136 9.5 BCS: Additional Regulatory Applications 138 9.6 Summary 138 References 139 10 Effects of Food on Drug Absorption 141 Zhu Zhou, Venugopal P. Marasanapalle, Xiaoling Li, and Bhaskara R. Jasti 10.1 Introduction 141 10.2 Mechanisms of Food Effects 147 10.3 Prediction of Food Effects 149 10.4 Summary 149 Abbreviations 150 References 150 11 Drug Metabolism in Gastrointestinal Tract 155 Rashim Singh, Dinh Bui, and Ming Hu 11.1 Introduction 155 11.2 Role of Intestinal Efflux Transporters in the Drug Disposition 161 11.3 Drug Metabolism–Transporter Coupling in Drug Disposition in GIT 163 11.4 Factors Affecting Intestinal Drug Metabolism 168 11.5 Biopharmaceutics Drug Disposition Classification System 170 11.6 Metabolism-Based Drug–Drug and Drug–Natural Product Interactions 171 11.7 Metabolic Interactions Between Gut Microbiome and Drugs in GIT 173 11.8 Metabolism-Based Xenobiotic-Induced Toxicity 174 11.9 GIT Metabolism-Based Drug-Designing and Lead Optimization in Drug Development 174 11.10 Summary 175 Abbreviations 176 References 176 12 Liver Drug Metabolism 189 Ritika Kurian, Leslie T. Steen, and Hongbing Wang 12.1 Introduction 189 12.2 Hepatic Structure and Function 189 12.3 Phase I Drug Metabolism 191 12.4 Phase II Drug Metabolism 199 12.5 Novel Platforms for Drug Metabolism Studies 204 12.6 Drug Metabolism and Its Impact on Adverse Drug Reactions 205 12.7 Conclusion 207 References 207 13 Urinary Excretion of Drugs and Drug Reabsorption 213 Jessica T. Babic, Jack Cook, and Vincent H. Tam 13.1 Introduction 213 13.2 Kidney as an Eliminating Organ 213 13.3 Drug Transporters and Their Role in Renal Elimination 220 13.4 Renal Elimination and Bioavailability 222 13.5 Augmented Renal Clearance 227 References 228 14 Excretion of Drugs and Their Metabolites into the Bile 233 Song Gao, Imoh Etim, Robin Sunsong, Christabel Ebuzoeme, Ting Du, and Dinh Bui 14.1 Introduction 233 14.2 Anatomy and Physiology of the Liver and Biliary System 234 14.3 Biliary Excreted Drugs and Metabolites 235 14.4 Impact of Biliary Excretion on ADME and Pharmacokinetics 235 14.5 Hepatic Transporters Involved in Biliary Excretion 245 14.6 Factors Affecting Biliary Secretion 248 14.7 Biliary Excretion Research Models 250 14.8 Concluding Remarks 255 Abbreviations 255 References 255 15 Pharmacokinetic Behaviors of Orally Administered Drugs 267 Hamdah Al Nebaihi, Dion R. Brocks, Jaime A. Yáñez, Marcus Laird Forrest, and Neal M. Davies Objectives 267 15.1 Introduction 267 15.2 Physicochemical Factors Affecting Oral Concentration Time Profiles 274 15.3 Physiological Factors Affecting Oral Concentration Time Profiles 281 15.4 Food-Effects and Oral Concentration Time Profiles 296 15.5 The Impact of the Lymphatic System on Oral Bioavailability 298 15.6 Summation 303 Abbreviations 304 References 304 16 In Vitro-In Vivo Correlations of Pharmaceutical Dosage Forms 315 Deliang Zhou and Yihong Qiu 16.1 Introduction 315 16.2 Categories of In Vitro-In Vivo Correlations 316 16.3 Convolution and Deconvolution 317 16.4 Development and Assessments of an IVIVC 321 16.5 Applications of an IVIVC 324 16.6 Challenges 325 16.7 Physiologically Based Biopharmaceutics Models (PBBM) 326 16.8 Summary 328 References 329 17 Advanced Concepts in Oral Bioavailability Research – An Overview 333 Baojian Wu, Min Chen, and Ming Hu Abbreviations 336 References 336 18 Expression and Pharmaceutical Relevance of Intestinal Transporters 339 Melanie A. Felmlee, Michael Ng, and Annie Lee 18.1 Introduction 339 18.2 Intestinal Drug Transport 340 18.3 Uptake Transporters 341 18.4 Efflux Transporters 350 18.5 Summary 353 References 353 19 Amino Acid Transporters 361 Liping Wang, Xiaoyan Li, Mengdi Ying, Ming Hu, and Zhongqiu Liu 19.1 Introduction 361 19.2 Classification of Amino Acid Transporters and their Functions 364 19.3 Epithelial Amino Acid Transporters 372 19.4 Endothelial Amino Acid Transporters 378 19.5 Regulation of Amino Acid Transport 380 19.6 Conclusion 382 Abbreviations 382 References 383 20 Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals 393 David J. Lindley, Stephen M. Carl, Dea Herrera-Ruiz, Li F. Pan, Lori B. Ward, Jonathan M.E. Goole, Olafur S. Gudmundsson, Matthew Behymer, and Gregory T. Knipp 20.1 Introduction 393 20.2 Transport Systems Mediating Peptide-based Pharmaceutical Absorption and Disposition: The Solute Carrier (SLC) Family 397 20.3 ATP Binding Cassette (ABC) Transporters 399 20.4 Gastrointestinal Tract-Specific Transporter Activity 400 20.5 Conclusions 407 Acknowledgments 408 References 408 21 OATP Transporters in Hepatic and Intestinal Uptake of Orally Administered Drugs 417 Wei Yue, Taleah Farasyn, Alexandra Crowe, Khondoker Alam, Lucila Garcia-Contreras, Yifan Tu, and Lu Wang 21.1 Introduction 417 21.2 Hepatic OATP1B1 and OATP1B 3 417 21.3 OATP2B1 in the Intestine 420 21.4 OATP1A2 in the intestine 421 21.5 Summary 422 Acknowledgement 422 References 422 22 ABC Transporters in Intestinal and Liver Efflux 429 Marilyn E. Morris and Tianjing Ren 22.1 Introduction 429 22.2 Apical Membrane Efflux Proteins 430 22.3 Basolateral/Lateral Membrane Efflux Proteins 442 22.4 Clinical Relevance of ABC Transporters in Oral Bioavailability of Drugs 444 22.5 Pharmacogenomics of ABC Transporters 445 22.6 Regulation of Efflux Transporters 445 22.7 Summary 446 Abbreviations 446 Acknowledgments 447 References 447 23 Interplay Between Metabolic Enzymes and Transporters 455 Zuoxu Xie, Lu Wang, Zicong Zheng, Yifan Tu, Yi Rong, Ming Hu, and Stephen Wang 23.1 Pathways and Functions of Drug Metabolic Enzymes and Transporters 455 23.2 Interplay Between Metabolic Enzymes and Transporters 462 23.3 Conclusion 467 References 468 24 Systemic Versus Local Bioavailability Enabled by Recycling 473 Yifan Tu, Lu Wang, and Ming Hu 24.1 Introduction 473 24.2 Systemic Bioavailability 473 24.3 Local Bioavailability 474 24.4 Factors Affecting Bioavailability 474 24.5 Enterohepatic Recycling (EHR) 475 24.6 Hepatoenteric Recycling (HER) 479 24.7 Enteroenteric Recycling (EER) 480 24.8 Summary 480 References 480 25 Intestinal Microbiome and Its Impact on Metabolism and Safety of Drugs 483 Xin Y. Chu and Paul C.L. Ho 25.1 Introduction 483 25.2 Direct Metabolism by Intestinal Microbiome 483 25.3 Indirect Mechanisms Affecting Drug Metabolism 489 25.4 Impact of Intestinal Microbiome on Drug Treatment in Clinical Practice 492 25.5 Conclusion and Future Perspectives 492 References 493 26 Drug–Drug Interactions and Drug–Dietary Chemical Interactions 501 Mengbi Yang, Yuanfeng Lyu, and Zhong Zuo 26.1 Introduction 501 26.2 Drug–Drug Interactions (DDIs) 501 26.3 Drug–Dietary Chemical Interactions in Oral Bioavailability 510 26.4 Summary 517 Abbreviations 517 References 518 27 Regulatory Considerations in Metabolism- and Transport-Based Drug Interactions 523 Xinning Yang, Sue-Chih Lee, Xinyuan Zhang, and Lei Zhang Disclaimer 523 27.1 Overview of Drug–Drug Interactions 523 27.2 Regulatory Recommendations of DDI Studies 527 27.3 Highlights of the Final Guidances for Industry: In Vitro and Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions 528 27.4 Role of Physiologically Based Pharmacokinetic (PBPK) Modeling in DDI Assessment 544 27.5 A Labeling Example to Illustrate the Translation of Complicated Drug Interaction Results to Labeling: Tipranavir 547 27.6 Examples to Illustrate the Use of PBPK in Supporting Labeling for Drugs that are Dual CYP3A/P-GP Substrates 549 27.7 Summary 549 Acknowledgement 550 References 550 28 Formulation Approaches to Improve Oral Bioavailability of Drugs 559 Zeren Wang, Chandan Bhugra, and Shun Chen 28.1 Introduction 559 28.2 Theoretical Considerations for Formulation Development of Poorly Water-Soluble Drugs 560 28.3 Formulation Considerations for the Development of Poorly Water-Soluble Drugs 563 28.4 Other Formulation Approaches 571 References 571 29 Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems 575 Pushkaraj Wagh, Jonathan Moreno, Christopher Nayar, and Jeffrey Wang 29.1 Introduction 575 29.2 Lipid-based Drug Delivery Systems 575 29.3 Advantages and Limitations of Lipid-Based and Self-Emulsifying Drug Delivery Systems 586 29.4 Summary 586 References 586 30 Oral Delivery of Nanoparticles: Challenges and Opportunities 591 Qing Lin, Ling Zhang, and Zhirong Zhang 30.1 Introduction 591 30.2 Role of Nanoparticle Shape, Size, and Surface in Oral Delivery of Nanoparticles 592 30.3 Characterization Methods of Nanoparticles for Oral Delivery 593 30.4 State-of-the-Art Carriers Designed and Applied in Oral Delivery of Nanoparticles 594 30.5 Challenges and Coexisting Opportunities 594 References 595 31 Oral Delivery of Therapeutic Peptides: Strategies for Product Development 599 Puchun Liu 31.1 Introduction 599 31.2 Overview of Approaches to Enabling Oral Peptide Delivery 604 31.3 Observation and Data Analysis of Low BA with Large Variabilities 607 31.4 Recommended Strategies for Oral Peptide Product Development 609 Abbreviations 613 References 613 32 Prodrugs to Improve Oral Delivery 619 Arjun D. Patel, Shuchi Gupta, and Mamoun Alhamadsheh 32.1 Introduction 619 32.2 Factors Associated With Oral Drug Absorption 620 32.3 Intestinal Physiology and Background 620 32.4 Strategies to Improve the Bioavailability of Orally Administered Drugs 621 32.5 Prodrug Overview and Classification 622 32.6 Prodrug Strategies to Improve Aqueous Solubility 630 32.7 Prodrug Approaches for Enhancing Absorption 631 32.8 Prodrug Approaches for Targeting Enzymes 631 32.9 Prodrug Approaches for Targeting Membrane Transporters 632 32.10 Conclusion 633 Abbreviations 634 References 634 33 Gastroretentive Drug Delivery Systems 637 Vrushali Waknis and Ajit S. Narang 33.1 Introduction 637 33.2 Oral Drug Delivery – Challenges and Opportunities 637 33.3 Human Gastric Physiology Relevant to GRDDS Design 638 33.4 Technologies 639 33.5 New Drug Development Considerations 645 33.6 Commercial GRDDS Products and Investigational New Products 649 33.7 Future Outlook 653 Acknowledgments 654 References 654 34 Enhancing Oral Bioavailability Using 3D Printing Technology 657 Timothy Tracy, Senping Cheng, Lei Wu, Xin liu, and Xiaoling li 34.1 Introduction 657 34.2 3D Printing in Pharmaceutical Applications 657 34.3 Novel Tablet Structures Possible with 3D Printing 660 34.4 Application of 3D Printing in Oral Bioavailability Enhancement 663 34.5 Future Outlook for 3D Printing and Bioavailability Enhancement 672 34.6 Summary 673 References 673 35 Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, Monkeys, and Humans 677 Ayman El-Kattan 35.1 Introduction 677 35.2 Determinants of Oral Bioavailability 677 35.3 Summary 691 References 691 36 In Vivo Methods for Oral Bioavailability Studies 701 Ana Ruiz-Garcia and Marival Bermejo 36.1 Introduction 701 36.2 Factors that Affect Oral Availability 701 36.3 In Vivo Animal Techniques 706 36.4 Animals Used in Bioavailability Studies 706 36.5 General Considerations for Blood Sampling 708 36.6 Statistical Considerations for Data Handling. (AUC Calculations in Sparse Sampling Designs) 708 36.7 Practical Examples in Rat Model 709 36.8 Intestinal Perfusion (see also Chapter 42) 710 36.9 Mathematical Considerations 711 References 712 37 Caco-2 Cell Culture Model for Oral Drug Absorption 715 Kaustubh Kulkarni, Lu Wang, and Ming Hu 37.1 Introduction 715 37.2 Description 717 37.3 Utility 719 37.4 Recent Progress 720 37.5 Significance of Caco-2 Cell Culture Model in Drug Discovery and Development 722 37.6 Example 722 37.7 Concluding Remarks 727 References 727 38 OATP Overexpressed Cells and Their Use in Drug Uptake Studies 729 Lu Wang, Zuoxu Xie, Yifan Tu, and Ming Hu 38.1 Introduction to OATP Cell Assay 729 38.2 Materials 731 38.3 Methods 731 38.4 Data Analysis 732 38.5 Notes 733 References 735 39 Use of Human Intestinal and Hepatic Tissue Fractions and Microbiome as Models in Assessment of Drug Metabolism and its Impact on Oral Bioavailability 737 Hani Zaher and George Zhang 39.1 Introduction 737 39.2 Gastrointestinal Tract and Absorption (see Also Chapter 5) 737 39.3 Mechanisms of Drug Absorption and Concept of Oral Bioavailability (see also Chapters 4–6) 738 39.4 Intestinal Metabolism and Oral Bioavailability (see Also Chapter 11) 739 39.5 In Vitro Systems Applied to Assess Intestinal Metabolism 740 39.6 In Vitro Systems Applied to Assess Human Hepatic First-Pass Metabolism (see Also Chapter 12) 743 39.7 Long-Term Hepatocyte Culture and Slow Metabolizing Drug Candidate 745 39.8 Microbiome and Absorption: A New Perspective 747 39.9 Summary 748 Acknowledgments 748 Abbreviations 749 References 749 40 Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion 757 Paresh P. Chothe, Sean Xiaochun Zhu, Sandeepraj Pusalkar, Chuang Lu, and Cindy Xia 40.1 Introduction 757 40.2 Liver Perfusion 758 40.3 Primary Hepatocytes 762 40.4 Organ Perfusion Versus Hepatocyte Studies 771 40.5 Perspectives 772 Acknowledgements 772 Abbreviations 772 References 772 41 Determination of Regulation of Drug Metabolizing Enzymes and Transporters 779 Sergio C. Chai, Taosheng Chen, and Wen Xie 41.1 Introduction 779 41.2 In vivo Methods 779 41.3 In vitro Methods 784 41.4 Biochemical, Biophysical and Structural Analysis of NRs Using Purified Proteins 789 41.5 Conclusions 796 Acknowledgments 796 References 796 42 Intestinal Perfusion Methods for Oral Drug Absorptions 801 li li, Dinh Bui, Wei Zhu, and Eun-Jung (Zenobia) Jeong 42.1 Introduction 801 42.2 Application and Recent Development of the Intestinal Perfusion Method 801 42.3 Data Interpretation and Method Comparison 803 42.4 Common In Vitro Methods Studying Intestinal Permeability and Metabolism 803 42.5 Summary 807 42.6 Methodologies and Experimental Data Analysis 807 Acknowledgment 813 References 815 43 In Silico Prediction of Oral Drug Absorption 819 Jin Dong, Zhu Zhou, Yujuan Zheng, and Miki Susanto Park 43.1 Introduction 819 43.2 QSPR Modeling 819 43.3 PBPK Modeling 821 43.4 PBBM Modeling as a Subset of PBPK Modeling 823 43.5 Applications of PBPK/PBBM Modeling 824 43.6 PBPK Software 827 43.7 Summary 839 References 839 44 Computational Modeling of Drug Oral Bioavailability 843 Lon W.R. Fong, Beibei Huang, Rajan Chaudhari, and Shuxing Zhang 44.1 Introduction 843 44.2 Computational Modeling of Bioavailability 844 44.3 Conclusions 851 Acknowledgment 852 References 852 45 Blood–Brain Barrier Permeability Assessment for Small-Molecule Drug Discovery Using Computational Techniques 857 Yankang Jing and Xiang-Qun Xie 45.1 Introduction 857 45.2 Basic Principle of the BBB Permeation 857 45.3 Role of the BBB in Drug Delivery 858 45.4 Experimental Methods for Assessing BBB Permeability 858 45.5 Computational Method to Predict BBB Permeability 859 Abbreviations 867 References 867 Index 871

    2 in stock

    £212.40

  • Rossis Principles of Transfusion Medicine

    John Wiley and Sons Ltd Rossis Principles of Transfusion Medicine

    2 in stock

    Book SynopsisROSSI'S PRINCIPLES OF TRANSFUSION MEDICINE Transfusion Medicine impacts patients with hematologic, oncologic, and surgical conditions as well as all areas of critical care medicine and multiple areas of chronic care. This book aims to be the single best source for information related to any aspect or application of Transfusion Medicine. Contributors for the sixth edition have once again been drawn from various scientific, medical, and surgical disciplines. Thus, this book ranges from encouraging and managing donors, to collecting and preserving the blood, to matching it to the appropriate recipient, all the way to its clinical uses. It also extends these concepts to implantable tissue and regenerative medicine. Other sample topics covered within the work include: Contemporary issues in donation and transfusion: patient blood management, clinical and technical aspects of blood administration, and donor and patient HemovigilanceBlood components and derivatives: red blood cell metabolism, preservation and oxygen delivery, blood groups, and composition of plasmaApheresis, transplantation, and new therapies: hematopoietic growth factors, therapeutic phlebotomy and cellular apheresis, HLA antigens, alleles, and antibodiesHow Transfusion Medicine has been affected by the coronavirus pandemic, the role of pathogen reduction and other modern trends This book serves as a complete and comprehensive resource on Transfusion Medicine for clinicians who prescribe blood, students who expect to enter clinical practice, and for the scientists, physicians, nurses, technologists, and others who assure the quality and availability of blood services.Table of ContentsContributors Preface List of abbreviations Section I: Transfusion medicine from ancient times to the current pandemic Chapter 1. Transfusion in the new millennium – Ennio C. Rossi and Toby L. Simon Chapter 2. Disaster and the blood community (including COVID-19)-Ruth Sylvester and Louis M. Katz Chapter 3. Responding to the Regulatory Challenges during Emergencies and Epidemics- Peter Mark Section II: Blood donation Chapter 4 Recruitment and screening of donors and the collection of blood—Susan Rossmann, Mary Townsend and Toby L. Simon Chapter 5 Blood donor testing—Jed B. Gorlin and Nancy Van Buren Chapter 6 Acute adverse reactions after blood donation– Anne F. Eder Chapter 7 Chronic effects of blood and plasma donation—Bryan Spencer and T. Simon Chapter 8 Global perspective: ensuring blood and blood product safety and availability through regulation and certification-Eva D. Quinley Section III: Blood groups and pretransfusion testing Chapter 9 Carbohydrate blood groups- Laura Cooling Chapter 10 Rh and LW blood group antigens- Connie M. Westhoff, Don L. Siegel, and Aline Floch Chapter 11 Other protein blood groups- Jill Storry and Jennifer Ricci Hagman Chapter 12 Molecular and routine compatibility testing–Connie Westhoff Section IV: Blood components Part A. Red cells Chapter 13 Red blood cell production and kinetics—Mark J. Koury and Lionel Blanc Chapter 14 Red cell metabolism, preservation and oxygen delivery—John Hess and Angelo D’Alessandro Part B: Platelets Chapter 15 Platelet production and kinetics- Christopher A. Tormey, Henry M. Rinder, and Thomas C. Binns Chapter 16 Platelet immunology and alloimmunization- Cheryl L. Maier and Seema R. Patel and H. Clifford Sullivan Chapter 17 Preparation, preservation, and storage of platelet concentrates- Moritz Stolla and Valery J. Li and Johnathan P. Mack Part C: White cells Chapter 18 Neutrophil production and kinetics: neutropenia and neutrophilia- Lawrence Rice and Eric Salazar Chapter 19 Granulocyte collection and transfusion- Jeffrey McCullough, Corrinne Goldberg and Jenny Petkova Part D: Plasma Chapter 20 Composition of plasma – Peter Hellstern Chapter 21 Plasma and cryoprecipitate for transfusion including SD plasma- Simon Stanworth and Toruma Apelseth Chapter 22 The purification of plasma proteins for therapeutic use- Nathan Brinkman, Karl McCann, and Barry Gooch Chapter 23 Immunoglobulins Products- Melvin Berger Section V: Apheresis Chapter 24 Basic principles of apheresis and the collection of blood components by apheresis- Jeffrey L. Winters and Edwin A. Burgstaler Chapter 25 Therapeutic apheresis: Plasma processing – Patricia A.R. Brunker and Monica B. Pagano Chapter 26 Therapeutic phlebotomy and specialized hemapheresis- Patricia Brunker and Jeffey Bailey Section VI: Blood transfusion Chapter 27 Patient blood management- Darrell J. Triulzi and Jansen N. Seheult and Mark H. Yazer and Jonathan H. Waters Chapter 28 Clinical and technical aspects of blood administration – Edward S. Lee, Debra L. Mraz, and Edward L. Snyder Chapter 29 Anemia and RBC transfusion- Jeff Carson Chapter 30 Sickle cell disease, thalassemia, and hereditary hemolytic anemias-Ross M. Fasano, Emily Riehm Meier and Satheesh Chonat Chapter 31 Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria-Christopher A. Tormey and Alexa J. Siddon Chapter 32 Hemolytic disease of the fetus and newborn- Megan Delaney, Wen Lun, Jennifer Webb Chapter 33 Obstetric transfusion practice- Roback Chapter 34 Transfusion in Infants and Children-Jeanne E. Hendrickson and Cassandra D. Josephson Chapter 35 Thrombocytopenia and platelet transfusion-Michael F. Murphy, Lise J Estcourt and Simon J. Stanworth Chapter 36 Immune mediated Thombocytopenia- Theodore Warkentin, Donald Arnold, Ishac Nazi, and James W. Smith Chapter 37 Coagulation Concentrates for Inherited Bleeding Disorders—Robert F. Sidonio and Gary M. Woods Chapter 38 Coagulation factor concentrates and pharmacologic therapies for acquired bleeding disorders- Ravi Sarode and Natalie Bavli Chapter 39 Perioperative transfusion practice- James R. Stubbs, Allan Klompas, and Leanne Thalji Chapter 40 Transfusion therapy in the care of trauma and burn patients- John R. Hess, Eileen M. Bulger, Benjamin Huebner, and Samuel Mandell Chapter 41 Transfusion support for the oncology patient- Kristin M. Stendahl, Wade L. Schulz, Edward L. Snyder Chapter 42 Pathogen reduction of blood components- Snyder and McCullough Section VII: Adverse sequelae of transfusion Chapter 43 Hemovigilance: weighing transfusion risks and benefits- Scott Kopesell Chapter 44 Transfusion transmitted virus infections-Erhard Seifried Chapter 45 Transfusion transmission of parasites and prions - Bryan Spencer and Paula Saa Chapter 46 Bacterial Contamination of Blood Components- Evan M. Bloch, Richard J. Benjamin and Sandra Ramirez Chapter 47 Hemolytic transfusion reactions- Celina Montemayor Garcia and Sandhya R. Panch Chapter 48 Febrile, allergic, and nonimmune transfusion reactions- Emmanuel A. Fadeyi and Gregory J. Pomper Chapter 49 Transfusion-related lung injury- Ulrich Sachs and Johnathan P. Wallis Chapter 50 Transfusion-associated graft-versus-host disease- Eric A. Gehrie and Courtney E. Lawrence Chapter 51 Transfusion-associated iron overload- Sujit Sheth Section VIII: Cellular and tissue transplant technologies Chapter 52 Hematopoetic growth factors and Cytokines-David Kuter Chapter 53 Hematopoetic stems cells and transplantation- Garrett S. Booth Chapter 54 HLA antigens, alleles, and antibodies—Harold Clifford Sullivan, Robert A. Bray, Howard M. Gebel and Scott M. Krummey Chapter 55 Car-T cells and other cellular immunotherapies- Don Siegel and Andrew Fesnak Chapter 56 Gene therapy applications to transfusion medicine-Diane S. Krause, Seena Tabibi, Emanuela M. Bruscia and Eric A. Gehrie Chapter 57 Tissue engineering and regenerative medicine-Julie G. Allickson Chapter 58 Human Tissue Allografts: Following the Path from Donor to Recipient - Matthew J. Kuehnert and Cassandra D. Josephson Index

    2 in stock

    £189.00

  • MultiDrug Resistance in Cancer

    John Wiley & Sons Inc MultiDrug Resistance in Cancer

    2 in stock

    Book SynopsisMULTI-DRUG RESISTANCE IN CANCER The book details the mechanisms underlying multi-drug cellular resistance and the targets of novel chemotherapeutic agents. Cancer is a major killer all over the world. Even with all the progress made, chemotherapy is still the mainstay of modern cancer treatment. The progression of the cellular defeat of numerous independent anticancer drugs in terms of their chemical structure is a major barrier to successful chemotherapy. Multi-drug resistance (MDR) is a term for the fact that most cancer patients exhibit this phenomenon. According to the numbers, drug resistance carries the blame for 90% of cancer patient deaths. Refractory cancer and tumor recurrence are common outcomes of prolonged chemotherapy. Because of the prevalence of drug-resistance mutations, the difficulty of treating tumors increases and the therapeutic efficacy of drugs decreases. Multi-Drug Resistance in Cancer: Mechanism and Treatment Strategies conTable of ContentsForeword xiii Preface xv Acknowledgment xvii 1 Multi- Drug Resistance in Cancer: Understanding of Treatment Strategies 1 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 1.1 Introduction 1 1.2 Both Congenital and Developed Resistance to Drugs 3 1.2.1 Intrinsic Resistance 3 1.2.2 Acquired Resistance 4 1.3 Drug- Resistance Mechanisms 6 1.3.1 Increased Efflux of Drugs 6 1.3.2 Impact on Medication Target 7 1.3.3 Improved DNA- Damage Repair 9 1.4 Senescence Escape 9 1.5 Epigenetic Alterations 9 1.6 Tumor Heterogeneity 10 1.7 Tumor Microenvironment 11 1.8 Epithelial to Mesenchymal Transition 13 1.9 Conclusion 15 References 18 2 Understanding Different Mechanisms Involved in Cancer Drug Resistance: Proposing Novel Strategies to Overcome MDR 31 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 2.1 Introduction 31 2.2 Drug Resistance: Internal and External Variables 33 2.2.1 Phenotypic Variation of Tumors 33 2.2.2 Tumor Microenvironment 33 2.2.3 Cancer Stem Cells 33 2.2.4 Inactivation of the Anticancer Drugs 34 2.2.5 Multi-Drug Resistance 35 2.2.6 Increasing the Release of Drugs Outside the Cell 35 2.2.7 Reducing the Absorption of the Drugs 36 2.2.8 Inhibition of Cell Death (Apoptosis Pathway Blocking) 36 2.3 Improving the Pharmacokinetics 37 2.4 Changing the Aim of the Chemotherapy Agents 37 2.5 Improving the DNA Repair Process 39 2.5.1 Augmentation of a Gene 39 2.5.2 Epigenetic Altering Caused Drug Resistance 39 2.6 MicroRNA in Cancer Drug Resistance 40 2.7 Conclusion 41 References 41 3 Molecular Mechanism of Multi-Drug Resistant Cancer Cells 47 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 3.1 Introduction 47 3.2 Types of Drug Resistance 48 3.3 Mechanisms of Drug Resistance 49 3.3.1 Drug Efflux via ABC Transporters 49 3.3.2 Permeability Glycoprotein/MDR- 1 51 3.3.3 Multi-Drug Resistance Protein 52 3.3.4 Breast Cancer Resistance Protein 53 3.4 Reduction in Drug Activity and Cellular Absorption 54 3.5 Instability in the Genome and Medication Resistance 56 3.5.1 Mutation and Medication Target Alteration 56 3.5.2 Restoration of DNA Integrity 57 3.5.3 Resistant Genes and Epigenetic Modifications 58 3.5.4 Drug Resistance and Programmed Cell Death 59 3.6 RNA Interference Therapy 62 3.7 Methods of Physical Intervention to Treat MDR 64 3.8 Conclusion 65 References 66 4 Natural Products for Clinical Management of Drug Resistant Cancer Cells 77 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 4.1 Introduction 77 4.2 Resistance Mechanisms 78 4.3 Antitumor Plants for Multi-Drug- Resistant Cells 79 4.4 Qualea Species and Their Medical Applications 82 4.5 Antitumor Activity of Qualea Grandiflora and Qualea Multiflora 83 4.6 Conclusion 83 References 84 5 Understanding of Autophagy to Combat MDR During Anticancer Therapy 87 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 5.1 Introduction 87 5.2 Mechanisms of Autophagy 89 5.2.1 Phagophore Assembly 89 5.2.2 Autophagosome Formation and Maturation 90 5.2.3 Autolysosome Degradation 90 5.2.4 Core Regulator of Autophagy 90 5.3 Mechanisms of MDR 91 5.4 Correlation Between Autophagy and Multi-Drug Resistance 92 5.5 The Cytoprotective Effect of Autophagy in the Regulation of Multi-Drug Resistance 93 5.6 Increased Autophagy Facilitates Multi-Drug Resistance 93 5.7 Autophagy Inhibition Improves Chemotherapy in MDR Cancers 95 5.8 Overcoming MDR With Autophagic Cell Death 96 5.9 Autophagy Kills Apoptosis- Deficient MDR Cancer Cells 97 5.10 Autophagy Promotes Chemosensitivity 97 5.11 Conclusion 98 References 99 6 Transporter Inhibitors: A Chemotherapeutic Regimen to Improve the Clinical Outcome of Colorectal Cancer 105 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 6.1 Introduction 106 6.2 CRC Transporters or ATP- Binding Cassette 107 6.2.1 ABC Transporter Family 107 6.2.2 ABC Transporters and CRC Initiation 108 6.2.3 ABC Transporters and the Resistance of Cancer Cells to Chemotherapy 109 6.3 Clinical Evidence for the Function of ABC Transporters in CRC MDR 111 6.3.1 Intrinsic Drug Resistance in Colon Cancer Upregulation of P- gp at Detection 111 6.3.2 Proliferating Tumor Cells Have MRP1 on Their Surface 112 6.4 General Approaches 113 6.5 By Blocking Tyrosine Kinase Inhibitors from Inhibiting MDR Transporters 115 6.6 Components Produced from Natural Sources that Inhibit MDR Transporters 116 6.7 Inhibiting ABC Transporters in Other Ways for CRC MDR Circumvention 117 6.8 Challenges and Future Prospective 118 6.9 Conclusion 119 References 119 7 Epithelial to Mesenchymal Transition (EMT): Major Contribution to Cancer Drug Therapy Resistance 131 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 7.1 Introduction 131 7.2 EMT and Tumor Resistance: In Vitro, In Vivo, and Clinical Trials 132 7.3 Tumor Microenvironment Regulates EMT 136 7.3.1 Hypoxia 138 7.3.2 The Extracellular Matrix 139 7.3.3 The Inflammatory and Immune Microenvironment 139 7.3.4 EMT Microenvironment: Medication Resistance 140 7.4 Drug Resistance and EMT Bioinformatics 142 7.4.1 Bioinformatics and Pharmacogenomics to Optimize Drugs and Targets and Identify Medication Resistance 142 7.4.2 Drug Resistance: Hereditary or Acquired 144 7.4.3 Therapies for EMT- Induced Medication Resistance 144 7.5 Conclusion 145 References 146 8 Advances in Metallodrug- Driven Combination Therapy for Treatment of Cancer 155 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 8.1 Introduction 156 8.2 Cancer Treatment Using Combination Therapy 159 8.3 Combined Treatment with Metallodrugs for Cancer Treatment 160 8.3.1 Platinum Metallodrugs 161 8.4 Nonplatinum Metallodrugs 164 8.5 Conclusion 166 References 167 9 Novel Strategies Preventing Emergence of MDR in Breast Cancer 171 Rishabha Malviya, Arun Kumar Singh and Deepika Yadav 9.1 Introduction 171 9.2 Breast Cancer Categorization and Epidemiological Studies 172 9.2.1 Treatment Options for Women With Breast Cancer 173 9.3 Multi-Drug Resistance in Breast Cancer 174 9.3.1 Breast Cancer Chemoresistance 174 9.3.2 Multi-Drug Resistance and ABC Channels in Breast Cancer 174 9.4 Drug Efflux Transporters in Breast Cancer 175 9.4.1 Exocytosis Transporters in the Stem Cell Population of Breast Cancer 175 9.4.2 Drug Efflux Channel Upregulation in Breast Cancer 176 9.4.3 Techniques for Breast Cancer MDR Reversal 177 9.4.4 Direct Pharmacologic Inhibition With MDR Inhibitors 178 9.5 Excessive Synthesis or Overexpression of Transporters for the Expulsion of Drugs 181 9.6 Nanotherapeutic Approach for MDR Reversal 183 9.7 Breast Cancer’s MDR Cure Problems and Future Outlook 184 9.8 Conclusion 185 References 186 Index 195

    2 in stock

    £148.20

  • Medication Management in Care of Older People

    John Wiley and Sons Ltd Medication Management in Care of Older People

    1 in stock

    Book SynopsisMedication Management in Care of Older People is an accessible introduction to medication management and its role in the management of older people and their medicines. It addresses key issues in medication management, evaluates professional roles and clinical practice initiatives and explores healthcare policy and prescribing initiatives.Table of ContentsChapter 1: Older People and Their Medicines: Health Objectives and Health Initiatives. Development of the National Service Framework (NSF) for older people. Management of medicines. The NHS Improvement Plan. Building a safer NHS for patients; the role of medication safety. Prescribing drugs. Dispensing medicines. Access to medicines- out of hours. The administration of drugs. Helping patients and carers to safely self administer medicines at home or in care homes. Community Matrons and the management of medicines. Patient case study. Chapter 2: The Physiology of Human Ageing. Homeostasis and ageing. Ageing and the cardiovascular system. Changes to the vascular system. Changes to cardiac tissue. Changes to cardiovascular function and control. Changes to cardiovascular cells. Implications for practice. Hepatic ageing. Changes to hepatic tissue. Changes to hepatic cells. Changes to hepatic molecular biology. Implications for practice. Renal ageing. Changes to tubular function. Implications for practice. Ageing and the immune system. Changes to organs and tissues. Changes to immune cells. Changes to immune molecules. Ageing and the inflammatory response. Chapter 3: The Application of Applied Pharmacology to the Older Person. Drug absorption. Factors that alter the absorption of drugs. Drug distribution. Drug metabolism. Factors affecting drug metabolism. Drug excretion. Biliary excretion. Pharmacodynamics. Receptor agonism. Pharmacodynamics and the effects of ageing. Chapter 4: Medication Management and the Older Person. Medication review and the older person. Medication review structure. The Single Assessment Process. Trigger questions. Care plans. Health care professional involvement. Prescribing practice. Principles of prescribing for the older person. Rational prescribing and prescribing support. Conclusions. Implications for practice. Chapter 5: Medication Errors and the Older Person. Introduction. The extent of the problem. The UK perspective. The potential dangers of medication errors. Definitions of medication error. Classification of medication errors. Causes of medication error. Forms of medication error. Medication errors that arise due to the supply and administration of medicines. Factors contributing to the development of medication errors. The nurse prescriber’s role in the prevention of medication errors. Prescription writing education. Preventative measures involving prescriptions. Computerised prescribing systems. Conclusions. Implications for practice. Chapter 6: Concordance with Medication and Older People. Introduction. Difficulties establishing a rationale. Characteristics of the non-concordant individual. Psychological theory. Medication related issues that underpin non-concordance. i. Polypharmacy and complicated medication regimens. ii. Lack of education. iii.Patient comprehension of the need to adhere to prescribed medication. administration protocols. Promoting concordance with medication regimens. Patient self-medication schemes. The prescriber’s role in the augmentation of concordance with medication for. older people. The art of teaching. Teaching practicalities. Reinforcing education. Barriers to teaching. Time management difficulties. Planning early discharge. Comprehension of applied pharmacology and therapeutics. Conclusions. Implications for practice. Chapter 7: Neurophysiology, and Neuropathology of Ageing. Introduction. In search of a nerve cell. Neurochemicals and synaptic transmission. Major neurotransmitters in the brain. The dynamic neurone, plasticity and memory. Changes in neuronal activity and communication in the ageing brain. What causes cellular damage with ageing. Neuropathology of Alzheimer’s disease. Pharmacological strategies. Neuropathology of Parkinson’s disease. Pharmacological approach in the treatment of PD. Conclusions. Implications for practice. Chapter 8: The Management of the Older Person with a Long-term Condition. Introduction. Government policy and long-term conditions. The NHS Improvement Plan. The evolvement of the community matron. The education and training of the community matron. Case finding and case management. Interprofessional working. Lay carer’s role. The future management of older people with long-term conditions. Conclusions. Implications for practice. Chapter 9: The Community Pharmacist’s Role in the Management of Older People and their Medicines. Introduction. Education and training Community pharmacy contractual framework. Repeat dispensing. Medicine Use Reviews (MUR’s). Medication Review. Services to residential homes Swallowing difficulties Domiciliary visiting schemes. Compliance aids. Physical problems. Prescribing support Multidisciplinary working. Conclusions. Implications for practice.

    1 in stock

    £52.20

  • Pain Management

    John Wiley and Sons Ltd Pain Management

    1 in stock

    Book SynopsisConventional pharmaceutical approaches to pain management are not always successful. Using only those medications that have an official indication for a certain condition reduces substantially the chance of the patient gaining pain relief and may expose them to intolerable side effects. However evidence now exists on the use of other drugs, produced for non-pain conditions, and how they can substantially increase the chances of pain relief. Covering the most recent developments in this field, McCleane offers an alternative solution to pain treatment when conventional treatments fail. This pioneering book proposes evidence-based alternatives to current options in pain management, using well-grounded rationales for each given treatment. This book is an ideal reference for the specialist and non-specialist prescriber alike and for practitioners from a wide variety of disciplines. It provides the evidence required and treatment algorithms for readers to use the drugs apprTrade Review“The author is clearly an expert in all of the topics covered in the book. It is one of the few books that offers a well informed, thoughtful discussion of the off-label use of a wide variety of drugs in the treatment of pain and is a valuable addition to the literature. This is a terrific quick reference that should be readily available in any clinic where patients with pain are managed.” (Doody's Book Reviews, November 2008)Table of ContentsForeword. 1 Introduction. 2 Conventional Pain Treatment. 3 Using Drugs Outside Their Licensed Indication. Part 1. 4 Topical Nitrates. 5 Topical Tricyclic Antidepressants. 6 Topical Opioids. 7 Topical Local Anesthetics. 8 Topical Glutamate Receptor Antagonists. 9 Topical, Oral, and Perineural-Adrenoreceptor Agonists. 10 Lamotrigine. 11 5HT3 Antagonists. 12 Cholecystokinin Antagonists. 13 Parenteral Anti-epileptics. 14 Intravenous Lidocaine. 15 L-Carnitine. 16 Other Pharmacological Options (Botulinum, Cimetidine, Glucosamine). Part 2. 17 Neuropathic Pain. 18 Complex Regional Pain Syndrome. 19 Joint Pain. 20 Fracture Pain. 21 Postoperative Pain. 22 Fibromyalgia. 23 Muscle Spasm and Pain. 24 Tendinopathies. 25 Low Back Pain. 26 Cancer Pain. Appendix: Suggested Doses and Modes of Administration of Novel Pharmacological Options. Index.

    1 in stock

    £84.56

  • Abrams Ten Drugs

    10 in stock

    Book SynopsisTrade Review“An expert, mostly feel-good book about modern medicine.” -- Kirkus“Lucidly informative and compulsively readable.” -- Publishers Weekly“Hager’s book is entertaining, insightful, and recommended” -- Booklist"[an] absorbing new book" -- The New York Times Book Review"A compelling look at the serendipitous discovery of ten modern medicines, as well as useful discussions about the wider problems facing today’s pharmaceutical industry... This well-written book offers a captivating backstory of each of the selected drugs and how, as the book’s subtitle suggests, they shaped the history of medicine." -- The Pharmaceutical Journal"In his book Ten Drugs: How Plants, Powders, and Pills Have Shaped the History of Medicine, Thomas Hager explores the landmark drugs that changed medical practice, finding out how they were discovered, what goes into making them and why they made such a significant impact on our society." -- BBC Science Focus

    10 in stock

    £18.04

  • Taylor & Francis Inc Poisoning and Toxicology Handbook

    Out of stock

    Book SynopsisA unique reference containing detailed reviews of more than 900 drugs and poisons, the Poisoning and Toxicology Handbook, Fourth Edition provides the latest information on medicinal, biological, herbal, and non-medicinal agents, and antidotes. Increasing its depth and scope with analyses of newer drugs, chemicals, and environmental toxins, including drugs that have been recently approved by the FDA, this book is a compendium of useful resources. The present volume provides locations and phone numbers of poison control centers throughout the country, organizations offering information on toxicology, and teratology information services. It presents diagnostic testing and analytical procedures, evaluates the effectiveness of antidotes, and features an extensive symptoms listing. The section on special topics provides detailed treatment protocols, hospital preparedness guidelines, position statements, and practice guidelines focused on the treatmeTrade Review"This is a wonderful book! Clinical laboratorians will find it a valuable tool for the laboratory reference book shelf."- Thomas P. Moyer, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"…a good reference for the clinician, medical student, and general toxicologist. The wealth of information is, for example, ideal for preparing for an examination on the clinical aspects of toxicology."- Matthew D. Reed, PhD, DABT"A valuable and complete, up-to-date, and accurate reference tool for the laboratory reference book shelf and resource specifically designed … . Split into six sections, the book provides a quick access to the latest and most relevant knowledge on poisoning and toxicology information … . A unique reference containing detailed reviews of more than 900 drugs and poisons alphabetically. These listings are current, including drugs that have been approved … within the past year. A valuable tool … in one of the most exciting and expanding fields in medical science by the authors who are well-known experts and lecturers in the fields of laboratory medicine and emergency toxicology."— Amritpal Singh Chohan, University of Birmingham in BTS Newsletter, Issue 32, 2008Table of ContentsMedicinal Agents. Nonmedicinal Agents. Biological Agents. Herbal Agents. Diagnostic Tests/Procedures. Antidotes and Drugs Used in Toxicology.

    Out of stock

    £204.25

  • Design of Caspase Inhibitors as Potential

    Taylor & Francis Inc Design of Caspase Inhibitors as Potential

    15 in stock

    Book SynopsisPresents the Therapeutic Potential for Caspase Inhibitors: Present and FutureCaspases represent one of the most specific protease families described to date. These extremely important enzymes are crucial to the destruction of aberrant cells the body's self-protection mechanism for warding off the growth of abnormal cells, many of which can promote cancer. Design of Caspase Inhibitors as Potential Clinical Agents introduces cutting-edge evidence regarding caspases' role in pro-inflammatory responses. New research now shows that the inhibition of caspase function is a critical component for the treatment of many diseases, including: Arthritic and neurological disorders Lung disease Hereditary fever syndromes Inflammatory boweTrade Review... can be a valuable reference source for scientist and students dealing with the medicinal chemistry and chemical biology aspects of apoptosis, inflammation and related diseases. -Dr. Enrique Perez-Paya, Centro de Investigacion Principe Felipe and CSIC (Spain) in ChemMedChem 2009Table of Contents Mammalian Caspase Activation Pathways in Apoptosis and Inflammation. Role of Caspases in Inflammation-Driven Diseases. Role of Caspases in Apoptotic-Driven Indications. Kinetics and Catalytic Activity of Caspases. Nonpeptide Small Molecule Inhibitors of Caspases. Identification of Inflammatory Caspase Inhibitors. Identification of Apoptotic Caspase Inhibitors. Discovery of a First-in-Class Apoptotic Caspase Inhibitor. Emricasan (PF-03491390/IDN-6556). Novel Approaches to Caspase Inhibitor Discovery. Therapeutic Potential for Caspase Inhibitors: Present and Future. Index.

    15 in stock

    £215.00

  • Bioactive Peptides

    Taylor & Francis Inc Bioactive Peptides

    15 in stock

    Book SynopsisFocuses on Biology, Pharmacology, and Therapeutic ApplicationsThe study and diverse applications of bioactive peptides traverse many sub-disciplines within chemistry, biology, physics, and medicine. Answering a long-standing need, Bioactive Peptides focuses on the biology, pharmacology, and therapeutic applications of endogenous peptide mediators and their analogues. Moving peptide science beyond chemical synthesis strategies and into the realms of peptide biology and therapeutics, it presents the overall contribution that peptide science has made to molecular, cellular, and whole organism biology, while also discussing future targets and therapeutic applications.Beneficial for Experts and Novices AlikePart I provides details of bioactive peptides that interact with common drug targets and analyzes some of the most competitive areasTrade ReviewThe book will be useful for researchers in protein chemistry and biochemistry, molecular biologists and physicians, and teachers and students of medical schools and universities specialized in proteomics. -G. Ya. Wiederschain, Doctor of Biological Sciences, in Biochemistry (Moscow)Table of ContentsRECEPTOR LIGANDS. NONRIBOSOMAL PEPTIDES. HOST-DEFENSE PEPTIDES AND ANTIMICROBIALS. VENOM COMPONENTS AND TOXINS.

    15 in stock

    £230.00

  • Quantitative Drug Design

    Taylor & Francis Inc Quantitative Drug Design

    15 in stock

    Book SynopsisSince the publication of the first edition, the field has changed dramatically. Scientists can now explicitly consider 3D features in quantitative structure-activity relationship (QSAR) studies and often have the 3D structure of the macromolecular target to guide the 3D QSAR. Improvements in computer hardware and software have also made the methods more accessible to scientists. Taking these developments into account, Quantitative Drug Design: A Critical Introduction, Second Edition shows scientists how to apply QSAR techniques at a state-of-the-art level.New to the Second Edition A new chapter on methods that identify the 3D conformations to use for 3D QSAR New discussions on partial least squares, multidimensional scaling, clustering, support vector machines, kNN potency prediction, and recursive partitioning Expanded case studies thatTable of Contents Overview of Quantitative Drug Design. Noncovalent Interactions in Biological Systems. Preparation of 3D Structures of Molecules for 3D QSAR. Calculating Physical Properties of Molecules. Biological Data. Form of Equations Relating Potency and Physical Properties. Statistical Basis of Regression and Partial Least-Squares Analysis. Strategy for the Statistical Evaluation of a Data Set of Related Molecules. Detailed Examples of QSAR Calculations on Erythromycin Esters. Case Studies. Methods to Approach Other Structure-Activity Problems.

    15 in stock

    £175.00

  • Copper Amine Oxidases

    Taylor & Francis Inc Copper Amine Oxidases

    1 in stock

    Book SynopsisAlthough the amount of research on copper amine oxidases has grown rapidly and substantially in the past decade, the field unfortunately suffers from lack of cohesion and significant confusion surrounds aspects as simple as confirmation of enzyme identities. This book describes the structure of the enzymes, the role of copper, and of the unusual cofactor 6-hydroxydopa quinine derived from a posttranslational modification of a tyrosine residue. It also covers the differences of between AOs from bacteria, plants, and mammals. Finally, the text examines the importance of this ubiquitous class of enzymes in physiology and in metabolism of biogenic amines.Table of ContentsHistory. Nomenclature and Potential Functions of Copper Amine Oxidases. Cofactors of Amine Oxidases: Copper Ion and Its Substitution and the 2, 4, 5-Trihydroxylphenylalanine Quinone. Copper Amine Oxidases from Plants. Soluble Copper Amine Oxidases from Mammals. Membrane-Bound Copper Amine Oxidases. Copper Amine Oxidase Genes. Mechanism of TPQ Biogenesis in Prokaryotic Copper Amine Oxidase. Copper Amine Oxidase Crystal Structures. Plasma Amine Oxidases in Various Clinical Conditions and in Apoptosis. Copper Amine Oxidases in Intestine Diseases. Copper Amine Oxidases in Adipose Tissue-Related Disorders. Copper Amine Oxidases in Adhesion Molecules in Renal Pathology and in Alzheimer’s Disease and VAP-1 in Leukocyte Migration. Inhibitors of Copper Amine Oxidases: Past, Present, and Future. Pharmacological Applications of Copper Amine Oxidases. Copper Amine Oxidases as Antioxidant and Cardioprotective Agents. Biotechnological Aspects of Copper Amine Oxidases. Concluding Remarks. References.

    1 in stock

    £190.00

  • Psychological Treatment of Medical Patients

    American Psychological Association Psychological Treatment of Medical Patients

    1 in stock

    Book SynopsisThis book shows mental health providers how to assess and treatsubstance use in medical settings. Clinical health psychologists often encounter patients needing interventions for substance use, yet rarely do practitioners receive specialized training in this area.Psychological Treatment of Medical Patients With Harmful Substance Use is designed for mental health providers in medical settings who need the knowledge and skills to assess and treat conditions relevant to substance use. This book is especially useful for mental health providers who treat adult medical outpatients for whom substance use is not their primary presenting problem. The authors clarify the distinction between nonharmful and harmful substance use, describe the signs and symptoms of substance use disorders, epidemiology, current models denoting biological and socio-cultural causes, and contributing factors (with an emphasis on cardiac, cancer, women’s health, and primary cTable of ContentsSeries Foreword IntroductionPart 1: Overview of Substance Use Chapter 1: Mental Health Professionals’ Guide to Understanding Harmful Substance Use Chapter 2: Etiology and Socio-Cultural Aspects of Harmful Substance Use Chapter 3: Levels of Care and Standard Treatments for Harmful Substance Use Chapter 4: Assessment and Brief Intervention for Harmful Substance Use in the Medical SettingPart II: Psychological Assessment and Intervention for Common Co-Morbid Problems Chapter 5: Assessment and Treatment of Depression Chapter 6: Assessment and Treatment of Anxiety Chapter 7: Assessment and Treatment of Sleep Dysregulation Chapter 8: Psychological Treatment of the Family Chapter 9: Relapse Prevention and Aftercare Chapter 10: Future Direction of Practice References Index About the Authors

    1 in stock

    £54.90

  • Pharmacology

    Elsevier Health Sciences Pharmacology

    Out of stock

    Book SynopsisIntroduces you to basic pharmacology principles, with an emphasis on applying them to the kinds of clinical situations you will encounter on the job. This title helps you learn about how different drugs work in the body, drug dosage calculation methods, drug administration routes and procedures, and more.Trade ReviewThe second edition of Pharmacology: Principles and Applications is a thorough, comprehensive pharmacology text that is well suited for health professions students as a result of its extensive content and effective use of review questions, exercises, color, icons, and graphics to engage students for optimal learning. The text is divided in such a manner that health professions faculty can easily determine which sections of the text should be emphasized in a specific discipline. Journal of Pharmacy Technology - November/December 2008Table of ContentsSection 1: General Aspects of Pharmacology 1. Legal and Ethical Aspects of Pharmacology 2. Basics of Pharmacology 3. Drug Information and Drug Forms 4. Understanding Drug Dosages for Special Populations 5. Reading and Interpreting Medication Labels and Orders and Documenting Appropriately Section 2: Mathematics for Pharmacology and Dosage Calculations 6. Math Review 7. Measurement Systems and Their Equivalents 8. Converting Between Measurement Systems 9. Calculating Doses of Nonparenteral Medications 10. Calculating Doses of Parenteral Medications Section 3: Medication Administration 11. Safety and Quality Assurance 12. Enteral Routes 13. Percutaneous Routes 14. Parenteral Routes Section 4: Pharmacology for Multisystem Application 15. Analgesics and Antipyretics 16. Immunizations and the Immune System 17. Anitmicrobials, Antifungals, and Antivirals 18. Antineoplastic Agents 19. Nutritional Supplements and Alternative Medicines Section 5: Medication Related to Body Systems 20. Endocrine System Disorders 21. Eye and Ear Disorders 22. Drugs for Skin Conditions 23. Musculoskeletal System Disorders 24. Gastrointestinal System Disorders 25. Respiratory System Disorders 26. Circulatory System and Blood Disorders 27. Urinary System Disorders 28. Reproductive System Disorders 29. Neurological System Disorders 30. Drugs for Mental Health and Behavioral Disorders 31. Drugs of Abuse and Misuse Appendices A. Check Your Understanding Answers B. Drug-Nutrient and Drug-Drug Interactions Glossary

    Out of stock

    £999.99

  • Dermatokinetics of Therapeutic Agents

    Taylor & Francis Inc Dermatokinetics of Therapeutic Agents

    1 in stock

    Book SynopsisNovel drug delivery technologies strive to bypass challenging biological layers to elicit desired pharmacological activity. The skin, one of our key defensive barriers, allows certain topically applied substances and toxins to pass. The dermatokinetics of a drug determines the efficacy of treatment of skin disorders.Presenting the first comprehensive reference on this important area of research, Dermatokinetics of Therapeutic Agents includes a general overview of the theoretical as well as practical aspects of dermatokinetics and addresses the impact of a drug delivery system on the dermatokinetics of drugs. Chapters and illustrations cover introductory aspects and the significance, methods, and models used in dermatokinetic studies of therapeutic agents.Topics include: Theoretical Models for Dermatokinetics of Therapeutic Agents Drug Delivery Approaches to Modulate Dermatokinetics of DrugsTable of Contents Introduction to Dermatokinetics. Theoretical Models for Dermatokinetics of Therapeutic Agents. Drug Delivery Approaches to Modulate Dermatokinetics of Drugs. Conventional Methods of Cutaneous Drug Sampling. Cutaneous Microdialysis. Sampling Substrates by Skin Permeablization. Spectroscopic Techniques in Dermatokinetics Studies. Dermatokinetics of Gene Therapeutics. Regulatory Perspective of Dermatokinetic Studies.

    1 in stock

    £195.00

  • Optimal Design for Nonlinear Response Models

    Taylor & Francis Inc Optimal Design for Nonlinear Response Models

    15 in stock

    Book SynopsisOptimal Design for Nonlinear Response Models discusses the theory and applications of model-based experimental design with a strong emphasis on biopharmaceutical studies. The book draws on the authors' many years of experience in academia and the pharmaceutical industry. While the focus is on nonlinear models, the book begins with an explanation of the key ideas, using linear models as examples. Applying the linearization in the parameter space, it then covers nonlinear models and locally optimal designs as well as minimax, optimal on average, and Bayesian designs. The authors also discuss adaptive designs, focusing on procedures with non-informative stopping. The common goals of experimental designsuch as reducing costs, supporting efficient decision making, and gaining maximum information under various constraintsare often the same across diverse applied areas. Ethical and regulatory aspects playTable of ContentsRegression Models and Their Analysis. Convex Design Theory. Algorithms and Numerical Techniques. Optimal Design under Constraints. Nonlinear Response Models. Locally Optimal Designs in Dose Finding. Examples of Optimal Designs in PK/PD Studies. Adaptive Model-Based Designs. Other Applications of Optimal Designs. Useful Matrix Formulae. Bibliography. Index.

    15 in stock

    £135.00

  • Chemistry of Natural Products

    Taylor & Francis Inc Chemistry of Natural Products

    1 in stock

    Book SynopsisThe second edition of a bestseller, this book discusses the common structural and stereochemical features of naturally occurring organic compounds. It includes a variety of examples to illustrate varied aspects so that the range of structure and behavior exhibited by these compounds is retained within the set framework. The author explores the increasing application of physical (spectroscopic) methods like IR, NMR, CD, ORD, MS, and High Resolution Mass Spectroscopy without undermining the importance of classical chemical methods. The section on problem solving helps to develop an analytical and critical evaluation of the data. Table of ContentsIntroduction. Structure. Stereochemistry. Reactions and Rearrangements. Synthesis. Biosynthesis. Biological Significance of Secondary Metabolites. Problems. Index.

    1 in stock

    £125.00

  • Carbohydrate Chemistry

    Taylor & Francis Inc Carbohydrate Chemistry

    15 in stock

    Book SynopsisThe second volume in the series Carbohydrate Chemistry: Proven Synthetic Methods, Volume 2 offers a collection of synthetic procedures valuable to the practice of synthetic carbohydrate chemistry. The series takes an important and unique approach in that all described procedures have been independently verified as reliable and reproducible. With editors and contributors who are highly respected scientists in the field, this book provides a widely useful reference for both researchers and students, exploring carbohydrate chemistry from both academic and industrial points of view.The book begins with an introductory section that offers tricks and tips collected by the series editor from many years of experience working in carbohydrate laboratories. The subsequent chapters present detailed protocols on both specific synthetic transformations and the preparation of common synthetic intermediates, with figures to aid in comprehension. Procedures are described for regioseleTrade Review'The contributors are the best scientists in the field and the series editor is highly respected. The volumes will ... be of use to undergraduates involved in carbohydrate workshops.'– Alexei Demchenko, Associate Professor of Chemistry and Biochemistry, Director of Graduate Studies, University of Missouri – St. Louis.‘This essential book series, focused on carbohydrate synthesis, starts with a dedication to Nobel Laureate Sir John W. Cornforth, who is credited with the first public criticism of what he pictured as ‘pouring a large volume of unpurified sewage into the chemical literature.’1 Unfortunately, this issue is not limited to the field of chemistry as many high profile cases of irreproducible experiments have led to alarms being set off even in the popular press.2 This series then serves as the much-needed water treatment plants – places where the reader can be guaranteed a good clean reproducible experiment. … at least now chemists with or without expertise in carbohydrates can count on finding reliable procedures to make sugar-based compounds at one scale – a major achievement. Not only should current practitioners gain back time lost in attempts to properly reconstruct experimental procedures, but these procedures should also allow more creative scientists to contribute to this growing area. Cornforth JW. Austr. J. Chem. 1993;46:157e70. For example, see Unreliable research: trouble at the lab. Econ. October 19, 2013.’ – Nicola L.B. Pohl, Indiana University, Department of Chemistry, Bloomington, IN, USA, for Carbohydrate Research, http://dx.doi.org/10.1016/j.carres.2015.04.007.Table of ContentsSection I: Synthetic Methods. Highly Stereoselective 1,2-cis-Glycosylations Employing C-2 (S)-(Phenylthiomethyl)benzyl Ether as a Chiral Auxiliary. Regioselective Reductive Openings of 4,6-O-Benzylidene-Type Acetals Using LiAlH4-AlCl3. A Facile Method for Oxidation of Primary Alcohols to Carboxylic Acids in Carbohydrate Synthesis. Ultrasonic Energy Promoted Allylation to Generate 1-C-(2,3,4,6-Tetra-O-benzyl-α-d-glucopyranosyl)prop-2-ene. Synthesis of a Multivalent Glycocyclopeptide Using Oxime Ligation. Reductive Amination Methodology for Synthesis of Primary Amines from Unprotected Synthons. General Preparation of Imidazole-1-sulfonate Esters. Regioselective Monoacylation and Monoalkylation of Carbohydrates Catalyzed by a Diarylborinic Ester. The Synthesis of Carbamates from Alkenylamines. Hydrolysis of Thioglycosides Using Anhydrous N-Iodosuccinimide (NIS) and Trifluoroacetic Acid (TFA). Highly Diastereoselective Construction of l-Heptosides by a Sequential Grignard Addition/Fleming-Tamao Oxidation. Synthesis of Fluorinated Exo-glycals Mediated by Selectfluor. A Direct and Stereospecific Approach to the Synthesis of α-Glycosyl Thiols. Efficient Microwave-Assisted Synthesis of 1′,2,3,3′,4,4′,6-Hepta-O-benzyl-sucrose and 1′,2,3,3′,4,4′-Hexa-O-benzylsucrose. Section II: Synthetic Intermediates. Oligosaccharide-Salicylaldehyde Derivatives as Precursors of Water-Soluble, Biocompatible Anion Receptors. Allyl 3,4,6-Tri-O-Benzyl-α-d-Mannopyranoside. Synthesis of a Spacer-Armed 6′-Sialyl-N-Acetyllactosamine. Synthesis of β-(1→3)-mannobiose. Phenyl 4,6-O-Benzylidene-1-thio-α-d-mannopyranoside. Synthesis of 1,3,4,6-Tetra-O-acetyl-α-d-glucopyranose Revisited. Synthesis of 4,6-O-Benzylidene Acetals of Methyl α-d-Glucopyranoside, Ethyl 1-Thio-β-d-gluco- and Galactopyranoside. Synthesis of α-N-Acetylneuraminic Acid Methyl Glycoside. Synthesis of Ammonium 3-Deoxy-d-manno-oct-2-ulopyranosylonate (Ammonium Kdo). Synthesis and Characterization of Tetra-O-propargyl Pentaerythritol. Improved Synthesis of Ethyl (2,3,4,6-Tetra-O-acetyl-β-d-galactopyranosyl)-(1→3)-4,6-O-benzylidene-2-deoxy-1-thio-2-trichloroacetamido-β-d-glucopyranoside. Synthesis of α-d-Galactofuranosyl Phosphate. Synthesis of 1,2 4,5-Di-O-(3,3-pentylidene)arabitol via Kinetic Acetal Formation. 1,2-Anhydro-3,4,6-tri-O-benzyl-β-d-mannopyranose. Synthesis of Glucosyl C-1 Dihalides from Tetra-O-acetyl-β-d-glucopyranosyl Chloride. Synthesis of 3,4,6-Tri-O-acetyl-d-galactal. Efficient Synthesis of Hepta-O-acetyl-β-lactosyl Azide via Phase Transfer Catalysis. Synthesis of 2,3,4,6-Tetra-O-acetyl-α-d-mannopyranosyl Azide. Synthesis of Phenyl 2,3,4,6-Tetra-O-acetyl-1-thio-β-d-galactopyranoside. An Alternative, Large-Scale Synthesis of 1,2 5,6-Di-O-isopropylidene-α-d-ribo-hex-3-ulofuranose.

    15 in stock

    £175.75

  • Rhodiola rosea

    Taylor & Francis Inc Rhodiola rosea

    15 in stock

    Book SynopsisThe genus Rhodiola (Family Crassulaceae) is indigenous to Northern Canada, Europe and Asia where its rhizomes and roots have been used for centuries for medicinal purposes. Recent interest in the species Rhodiola rosea (roseroot) in the West arose from the use of the rhizome as an adaptogen for the treatment of stress, but in the last few years, chemical and pharmacological studies have confirmed other valuable medicinal properties. Written by well-known researchers in this field of study, Rhodiola rosea examines important aspects of this increasingly important medicinal plant, including: Cultivation Taxonomy Ethnobotany Conservation Phytopathology Phytochemistry Pharmacology Biotechnology Trade Review"The book is written in clear, detailed scientific language useful for those studying Rhodiola. All published research results are described and well documented. Chapters are clearly identified and well referenced. The chapters are concisely written and wherever possible provided with tables. Each ends with a comprehensive list of references. The authors have succeeded in writing a clear book covering all aspects of recent research dealing with Rhodiola rosea. The book is a good reference book for scientists, herbalists and product developers working within the food supplement industry. It could also be useful for those writing legal claims in the commercialization of Rhodiola rosea." -Nancy Popieul, in Economic Botany "For professionals needing an authoritative text, clinicians, phytochemists, herb growers, pharmacognosists, and botanists, the wait is over. No matter which topics you find of interest, the well-written chapters will provide the reader with detailed and up-to-date information, impossible to find in any other single text. ...an essential text for anyone wanting to use, research, or grow this remarkable plant." -David Winston, RH(AHG), Herbal Therapeutics Research Library, David Winston's Center for Herbal Studies, Washington, New Jersey, in HerbalGram From the Foreword: "This book will become the touchstone and the essential reference for anyone serious about R. rosea as a future medicine ... . This volume clearly will provide researchers, health professionals, industry members, and others with a wide perspective and deep level of reliable information on this increasingly popular and beneficial medicinal plant." -Mark Blumenthal, Founder & Executive Director, American Botanical Council, Editor-in-Chief, HerbalGram & HerbClipTable of ContentsTaxonomy of Rhodiola rosea L., with Special Attention to Molecular Analyses of Nunavik (Québec) Populations. Ethnobotany and Conservation of Rhodiola Species. Phytochemistry of Rhodiola rosea. Cultivation of Rhodiola rosea in Europe. Rhodiola rosea Cultivation in Canada and Alaska. Diseases of Wild and Cultivated Rhodiola rosea. Biotechnology of Rhodiola rosea. Pharmacological Activities of Rhodiola rosea. Evidence-Based Efficacy and Effectiveness of Rhodiola SHR-5 Extract in Treating Stress- and Age-Associated Disorders. Rhodiola rosea in Psychiatric and Medical Practice. Toxicology and Safety of Rhodiola rosea. Commercialization of Rhodiola rosea. Index.

    15 in stock

    £175.00

  • Clinical Pharmacology and Practical Prescribing

    Taylor & Francis Ltd Clinical Pharmacology and Practical Prescribing

    1 in stock

    Book SynopsisThe Medicine on the Move series provides fully-flexible access to subjects across the curriculum, in this case clinical pharmacology and prescribing practice, in a combination of print and mobile formats. The books are ideal for the busy medical student and junior doctor, irrespective of individual learning style and whether they are studying a subject for the first time or revisiting it during exam preparation, providing the right information whenever and wherever it is needed. Readers can choose from the book and the eBook to suit different situations, enabling them to benefit from learning medicine on the move.Print Versions of this book also include access to the ebook version.Table of ContentsCLINICAL PHARMACOLOGY. DRUGS AND PRACTICAL PRESCRIBING. SELF-ASSESSMENT.

    1 in stock

    £31.99

  • John Wiley and Sons Ltd Inflammation and Allergy Drug Design

    Out of stock

    Book SynopsisThis book educates the reader on the molecular and cellular mechanism of allergic diseases in the respiratory tract covering all aspects, from its immunological basis to its application in drug development.Table of ContentsContributors, vii Preface, xiii Part I: Cells contributing to the pathogenesis of allergic diseases in the respiratory tract 1 Novel anti-infl ammatory drugs based on targeting lung dendritic cells and airway epithelial cells, 3 Bart N. Lambrecht, Maud Plantinga, Monique Willart, and Hamida Hammad 2 Role of Th2 cells in the allergic diathesis, 15 Marsha Wills-Karp 3 Importance of Th17- and Th1-associated responses for the development of asthma, 27 Tomohiro Yoshimoto, Hiroko Tsutsui, and Kenji Nakanishi 4 Regulatory T cells, 39 Chris Corrigan and Kimuli Ryanna 5 A role for natural killer T-cell subsets in the pathogenesis of various allergic disorders, 59 Hiroshi Watarai, Michishige Harada, Mayumi Tamari, and Masaru Taniguchi 6 Regulatory roles of B cells in allergy and infl ammation, 67 Kiyoshi Takatsu, Masashi Ikutani and Yoshinori Nagai 7 Mast cells, 79 Mindy Tsai and Stephen J. Galli 8 Eosinophils, 107 Nancy A. Lee, Mark V. Dahl, Elizabeth A. Jacobsen, and Sergei I. Ochkur 9 Basophils in infl ammation and allergy drug design, 123 Donald MacGlashan, Jr. 10 Epithelial cells, 139 Tillie-Louise Hackett, Stephanie Warner, Dorota Stefanowicz, and Darryl Knight 11 Fibroblasts, 149 Alastair G. Stewart, Lilian Soon, and Michael Schuliga 12 Airway smooth muscle cells, 163 Andrew J. Halayko and Pawan Sharma Part II: Cytokines contributing to the pathogenesis of allergic diseases in the respiratory tract 13 Interleukin 4, interleukin 13, and interleukin 9, 175 Kenji Izuhara, Shoichiro Ohta, Hiroshi Shiraishi, and Shoichi Suzuki 14 Interleukin 3, interleukin 5, and granulocyte–macrophage colony-stimulating factor, 187 Alba Llop-Guevara, Josip Marcinko, Ramzi Fattouh, and Manel Jordana 15 Interleukin 15, interleukin 17, and interleukin 25, 197 Hiroshi Nakajima and Itsuo Iwamoto 16 Thymic stromal lymphopoietin, 205 Kazuhiko Arima and Yong-Jun Liu 17 Interleukin 10, 215 Whitney W. Stevens, Larry Borish, and John W. Steinke 18 Tumor necrosis factor alpha, 225 Christopher Brightling, Latifa Chachi, Dhan Desai, and Yassine Amrani 19 Profi brotic and angiogenic factors in asthma, 237 Neville Berkman and Francesca Levi-Schaffer 20 Chemokines, 253 Luis M. Teran and Juan R. Velazquez 21 Epithelial growth factors, 263 Yasuhiro Gon and Shu Hashimoto Part III: Other mediators contributing to the pathogenesis of allergic diseases in the respiratory tract 22 Prostanoids, 273 Sarah A. Maher, Deborah L. Clarke, and Maria G. Belvisi 23 Leukotrienes, 285 Katsuhide Okunishi and Marc Peters-Golden 24 Proteases in allergy, 297 Keisuke Oboki and Hirohisa Saito 25 Toll-like receptors, 307 Jessica L. Allen, Aurelien Trompette, and Christopher L. Karp Index, 317

    Out of stock

    £104.36

  • An Introduction to Toxicology

    Springer London Ltd An Introduction to Toxicology

    1 in stock

    Book SynopsisThe Emergence of Modern Toxicology.- Core Concepts in Toxicology.- Toxicokinetics - The Fate of Chemicals within the Body.- Toxicodynamics - How Chemicals Induce Toxicity.- Fightback - Adaptive Responses to Toxicant Exposure.- Target Organ Toxicity: Liver and Kidney.- Chemical Toxicity to the Unborn.-Chemicals and Cancer.-Everyday Toxicology I - Alcohol.-Everyday Toxicology II - Tobacco. ? ? ?Trade ReviewFrom the book reviews:“I found this to be an excellent text book, in fact one of the best I have referred to in recent times. Whether one is a non-toxicologist seeking an overview of the subject or an Industrial Toxicologist working every day to tackle the issues of product development, there is something for everybody. … This book should be a point of reference for any modern toxicologist – it will be for me!” (Jim Ridings, bts News Magazine of The British Toxicology Society, Vol. 1 (2), September, 2014)Table of ContentsThe Emergence of Modern Toxicology.- Core Concepts in Toxicology.- Toxicokinetics - The Fate of Chemicals within the Body.- Toxicodynamics - How Chemicals Induce Toxicity.- Fightback - Adaptive Responses to Toxicant Exposure.- Target Organ Toxicity: Liver and Kidney.- Chemical Toxicity to the Unborn.- Chemicals and Cancer.- Everyday Toxicology I - Alcohol.- Everyday Toxicology II - Tobacco. ​ ​ ​

    1 in stock

    £71.24

  • Quantitative Pharmacology

    Taylor & Francis Ltd Quantitative Pharmacology

    1 in stock

    Book SynopsisPKPD awareness is vital if we are to attempt to relate preclinical results to the acute and long term consequences in humans. The debate on whether preclinical findings can be translated to the human usage is still engaging scientists across industry, academia and regulatory bodies. Pharmacokinetics (PK) and pharmacodynamics (PD) comprise traditionally distinct disciplines within pharmacology, the study of the interaction of drugs with the body. It is our intention to show that by deliberately, intimately and systematically integrate these disciplines our understanding of drugs and the efficiency and effectiveness of drug discovery and development may be greatly enhanced. The book is therefore written with a broad audience in mind and focuses on concepts. Pharmacologists of all sorts, safety scientists, pharmacokineticists, medicinal chemists, clinicians, statisticians, veterinarians, animal science professionals, project leaders and students of medical, pharmaceutical and veterinarTrade Review"… provides very attractive and comprehensive reading for a broad audience—inside as well as outside Pharma—with interest in integrating PK and PD observations for greater understanding of how to connect drug fate and treatment consequences in vivo."—Professor Arvid Carlsson, Nobel Laureate, Gothenburg University"I consider the book by Gabrielsson and Hjorth to be very useful for in depth studies by scientists working with drug development and experimentalists in clinical pharmacology. It combines the analysis of effects versus time patterns with kinetic corollaries in a most comprehensive way. Moreover, it is a book of great graphical beauty exceptionally styled with a cover painted by one of the authors."--Gunnar Alvan MD PhD, Emeritus professor and former Director General of the Swedish Medical Products Agency"… provides very attractive and comprehensive reading for a broad audience—inside as well as outside Pharma—with interest in integrating PK and PD observations for greater understanding of how to connect drug fate and treatment consequences in vivo."—Professor Arvid Carlsson, Nobel Laureate, Gothenburg University"I consider the book by Gabrielsson and Hjorth to be very useful for in depth studies by scientists working with drug development and experimentalists in clinical pharmacology. It combines the analysis of effects versus time patterns with kinetic corollaries in a most comprehensive way. Moreover, it is a book of great graphical beauty exceptionally styled with a cover painted by one of the authors."--Gunnar Alvan MD PhD, Emeritus professor and former Director General of the Swedish Medical Products AgencyTable of ContentsIntroduction - What is PK/PD and Quantitative Pharmacology. Principles of kinetics from a pharmacodynamic point of view. Principles of plasma protein binding. Principles of dose, time and flow dependencies. Principles of rapid concentration-response equilibria. Time delays between plasma concentration and response. Principles of inter-species scaling.

    1 in stock

    £152.56

  • Drug Delivery

    Taylor & Francis Inc Drug Delivery

    1 in stock

    Book SynopsisIntegrating the clinical and engineering aspects of drug delivery, this book offers a much needed comprehensive overview and patient-oriented approach for enhanced drug delivery optimization and advancement. Starting with an introduction to the subject and pharmacokinetics, it explores advances for such topics as oral, gastroretentive, intravitreal, and intrathecal drug delivery, as well as insulin delivery, gene delivery, and biomaterials-based delivery systems. It also describes drug delivery in cancer, cardiac, infectious diseases, airway diseases, and obstetrics and gynecology applications. Examining special clinical states requiring innovative drug delivery modifications, such as hypercoagulability often seen in pregnancy, cancer, and autoimmune diseases, the book also discusses methods for improved drug delivery in clinical settings using clinical end points, clinical trials, simulations, and other venues. It also describes the latest drug delivery advances involving nanomaterTrade Review"This book is an excellent approach to the state of art in drug delivery, with the advantage of the clinical view. It is a good starting point to connect very distant spheres of knowledge in a hot spot of advanced molecular controlled release."—Guillermo R. Castro, Universidad Nacional de La Plata, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina"…unique compilation of information in the area of drug delivery, and readers will find useful information not only for their present use but also for furthering science in this area." —Ambikanandan Misra, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, IndiaTable of ContentsAn Introduction of Key Concepts in Drug Delivery. An Introduction to Pharmacokinetics: From Conventional to Advanced Systemic Drug Delivery Systems. Transporters and Enzymes Targeted Prodrugs for Improved Oral Drug Delivery. Gastroretentive Delivery: Physicochemical, Biopharmaceutical, Technological and Regulatory Considerations. Invasive vs. Non-Invasive Delivery of Insulin. Artificial Pancreas Drug Delivery. Micro/Nano Devices for Drug Delivery. Microneedle-Mediated Vaccines. Application of Nanoparticle Tracking Analysis in Drug Delivery. Microsponges for Drug Delivery. Chitosan for Advancing Drug Delivery. Gene Delivery by Electroporation. Drug Delivery Systems for Infectious Diseases. Nanotechnology in Drug Delivery to Chronic Inflammatory Diseases. Intrathecal Drug Delivery. Cancer Stem Cell Drug Delivery. Cardiac Drug Delivery. Current Developments in Nano-Therapeutics for Airway Diseases. Intravitreal Drug Delivery. Drug Delivery in Obstetrics and Gynecology. Drug Delivery Systems: A Regulatory Perspective.

    1 in stock

    £135.00

  • Carbohydrate Chemistry

    Taylor & Francis Inc Carbohydrate Chemistry

    15 in stock

    Book SynopsisVolumes in the Proven Synthetic Methods Series address the concerns many chemists have regarding irreproducibility of synthetic protocols, lack of characterization data for new compounds, and inflated yields reported in chemical communicationstrends that have recently become a serious problem.Featuring contributions from world-renowned experts and overseen by a highly respected series editor, Carbohydrate Chemistry: Proven Synthetic Methods, Volume 3 compiles reliable protocols for the preparation of intermediates for carbohydrate synthesis or other uses in the glycosciences.Exploring carbohydrate chemistry from both the academic and industrial points of view, this unique resource brings together useful information into one convenient reference. To ensure reproducibility, an independent checker has verified the experimental parts involved by repeating the protocols or using the methods.The book includes new or more detailed versions ofTrade Review'The contributors are the best scientists in the field and the series editor is highly respected. The volumes will ... be of use to undergraduates involved in carbohydrate workshops.'– Alexei Demchenko, Associate Professor of Chemistry and Biochemistry, Director of Graduate Studies, University of Missouri – St. Louis.‘This essential book series, focused on carbohydrate synthesis, starts with a dedication to Nobel Laureate Sir John W. Cornforth, who is credited with the first public criticism of what he pictured as ‘pouring a large volume of unpurified sewage into the chemical literature.’1 Unfortunately, this issue is not limited to the field of chemistry as many high profile cases of irreproducible experiments have led to alarms being set off even in the popular press.2 This series then serves as the much-needed water treatment plants – places where the reader can be guaranteed a good clean reproducible experiment. … at least now chemists with or without expertise in carbohydrates can count on finding reliable procedures to make sugar-based compounds at one scale – a major achievement. Not only should current practitioners gain back time lost in attempts to properly reconstruct experimental procedures, but these procedures should also allow more creative scientists to contribute to this growing area. Cornforth JW. Austr. J. Chem. 1993;46:157e70. For example, see Unreliable research: trouble at the lab. Econ. October 19, 2013.’ – Nicola L.B. Pohl, Indiana University, Department of Chemistry, Bloomington, IN, USA, for Carbohydrate Research, http://dx.doi.org/10.1016/j.carres.2015.04.007.Table of ContentsSynthetic Methods. Synthetic Intermediates.

    15 in stock

    £210.00

  • Heterogeneous Catalysis

    Taylor & Francis Inc Heterogeneous Catalysis

    1 in stock

    Book SynopsisFor more than a century, bioactive heterocycles have formed one of the largest areas of research in organic chemistry. They are important from a biological and industrial point of view as well as to the understanding of life processes and efforts to improve the quality of life. Heterogeneous Catalysis: A Versatile Tool for the Synthesis of Bioactive Heterocycles highlights the recent methodologies used in the synthesis of such bioactive systems and focuses on the role of heterogeneous catalysis in the design and synthesis of various biologically active heterocyclic compounds of pharmacological interest. Topics include: Synthetic protocols for the construction of heterocyclic systems employing silica-bound catalysts Recent advances in heterogeneous copper-catalyzed reactions for the synthesis of bioactive heterocycles Features of silica-based heterogeneous catalysts, such as abundance, ease of use, and stabilityTable of Contents Synthesis of Bioactive Heterocyclic Systems Promoted by Silica-Supported Catalysts. Eco-Benign Synthesis of Indole Derivatives Employing Diverse Heterogeneous Catalysts. Solid Heterogeneous Catalysts Based on Sulfuric Acid and Transition-Metal Salts: Synthesis of Bioactive Heterocycles. Heterogeneous Copper-Catalyzed Synthesis of Bioactive Heterocycles. Silica Sulfuric Acid: A Simple and Powerful Heterogeneous Catalyst in Organic Synthesis. Application of Silica-Based Heterogeneous Catalysis for the Synthesis of Bioactive Heterocycles. Application of Organometallic Compounds as Heterogeneous Catalysts in Organic Synthesis. Ultrasound: An Efficient Tool for the Synthesis of Bioactive Heterocycles. Nano–Zinc Oxide: An Efficient Heterogeneous Catalyst for the Synthesis of Heterocyclic Compounds. Application of Heterogeneous Catalysts for the Synthesis of Bioactive Coumarins. Silver: A Versatile Heterogeneous Catalyst for Heterocyclic Synthesis. Mesoporous Materials from Novel Silica Source as Heterogeneous Catalyst.

    1 in stock

    £171.00

  • Cytochrome P450 2D6

    Taylor & Francis Inc Cytochrome P450 2D6

    1 in stock

    Book SynopsisCytochromes are proteins that catalyze electron transfer reactions of well-known metabolic pathways and are classified in various superfamilies. The CYP, or P450, superfamily accounts for 90% of the oxidative metabolism of clinical drugs. One member of this superfamily, P450 2D6 (or CYP2D6), singlehandedly metabolizes about 25% of all medications in the human liver. Cytochrome P450 2D6: Structure, Function, Regulation, and Polymorphism reviews the current knowledge of CYP2D6 as well as the maturing body of evidence indicating its significance to clinical and pharmacological researchers and practitioners.This book focuses on the critical role CYP2D6 plays in the human liver. It examines the genetic, epigenetic, physiological, pathological, and structural factors of the gene that govern the highly variable metabolism of a number of drugs in clinical use. It highlights the impact of the functional roles of CYP2D6 on clinical practice and drug development and also dTable of ContentsIntroduction to Human Cytochrome P450 Superfamily. Mammalian CYP2D Members: A Comparison of Structure, Function, and Regulation. Substrates of Human CYP2D6. Inhibitors of Human CYP2D6. Regulation of Human CYP2D6. Structure and Function of Human CYP2D6. Clinical Pharmacogenomics of Human CYP2D6. General Discussion about Human CYP2D6.

    1 in stock

    £237.50

  • Arabian Drugs in Early Medieval Mediterranean

    Edinburgh University Press Arabian Drugs in Early Medieval Mediterranean

    1 in stock

    Book SynopsisThis book explores the impact of Greek (as well as Indian and Persian) medical heritage on the evolution of Arab medicine and pharmacology, investigating it from the perspective of 'materia medica' a reliable indication of the contribution of this medical legacy.

    1 in stock

    £35.15

  • Adverse Drug Interactions

    Taylor & Francis Inc Adverse Drug Interactions

    1 in stock

    Book SynopsisAdverse Drug Interactions: A Handbook for Prescribers assists clinicians by providing key information on potential adverse effects that can result from prescribing two or more drugs for simultaneous use. Interactions that are likely to give rise to life-threatening conditions, and which must therefore be completely avoided, are clearly highlighted. Less threatening but nonetheless important interactions necessitating practical measures, such as frequent monitoring and advice to patients, are also discussed.Presented in a user-friendly format, the book is organised by drug class and provides a brief summary of the mechanism underlying a particular interaction, alternative drugs lacking the same reactions that may be considered, and instructions for monitoring patients when adverse effects occur. All interactions listed in the previous edition have been reviewed and updated using the latest information available. The clinical reality of tTrade Review“There is much to commend. There are useful preliminary sections on the complexity of drug–drug interactions and the emerging role of electronic decision support systems… I was particularly pleased to see the inclusion of interactions with herbal and common over-the-counter medications, alcohol, ‘classic’ recreational drugs, vitamins and minerals, and key food groups.”—Daniel Marks, University College London Hospital, London, British Journal of Hospital MedicineTable of ContentsDrugs Acting on the Cardiovascular System. Drugs Acting on the Central Nervous System. Anticancer and Immunomodulating Drugs. Anticoagulants. Antidiabetic Drugs. Other Endocrine Drugs. Analgesics. Musculoskeletal Drugs. Anesthetic Drugs: General. Drugs to Treat Infections. Drugs Acting on the Gastrointestinal Tract. Respiratory Drugs. Metabolic Drugs. Obstetrics and Gynecology. Drugs Used to Treat the Urinary System. Drugs of Abuse. Miscellaneous. Over-the-Counter/Online Drugs, Traditional and Herbal Remedies. Appendices.

    1 in stock

    £66.99

  • Fundamentals of Asymmetric Synthesis

    Taylor & Francis Inc Fundamentals of Asymmetric Synthesis

    1 in stock

    Book SynopsisAsymmetric synthesis is an integral part of synthetic organic chemistry. Some of the reactions in this book were known prior to 1980, while several new ones, particularly catalytic asymmetric reactions, have been discovered in the recent years. The impact of this new class of reactions has been impressively extensiveboth on organic and medicinal chemistry. These reactions have been accepted whole-heartedly by synthetic organic chemists in developing shorter routes for complex natural targets as well as in the manufacture of a wide range of drug intermediates.Table of ContentsIntroduction. Terms, Definitions and Concepts in Asymmetric Synthesis. Achiral and Chiral Molecules and Their Properties. Prochirality. Enantioselective and Diastereoselective Synthesis. Methods for Monitoring Enantioselective and Diastereoselective Synthesis. Methods for Inducing Asymmetry. Chiral Substrate Controlled Asymmetric Reactions: Diastereoselection in acyclic systems. Chiral auxiliary controlled asymmetric reactions—Asymmetric α-alkylations. Chiral Stoichiometric Reagent Controlled Asymmetric Synthesis: Chiral Boron Reagents. Chiral Catalyst Mediated Asymmetric Reactions: Enzymes. Chiral Organometallic Catalysed Asymmetric Reactions: Sharpless Asymmetric Epoxidations, Dihydroxylations and Aminohydroxylations. Chiral Organometallic Catalysed Asymmetric Reactions. Organocatalysts in Asymmetric Synthesis—Chiral Additive Mediated Reactions. Asymmetric Aldol Reaction. Asymmetric Diels–Alder reactions. Stereoselective Synthesis and Stereospecific Synthesis. Index.

    1 in stock

    £175.75

  • Clinical Pharmacology in Athletic Training

    Human Kinetics Publishers Clinical Pharmacology in Athletic Training

    3 in stock

    Book SynopsisAthletic trainers have a responsibility to provide high-quality pharmaceutical care while meeting both legal and ethical requirements. Clinical Pharmacology in Athletic Training empowers athletic trainers with a functional understanding of pharmacology that enables them to formulate a treatment plan intended to mitigate disease and improve the overall health of their patients. This text incorporates the most up-to-date content from the 2020 Commission on Accreditation of Athletic Training Education (CAATE) standards, and it emphasizes interprofessional practice to enable future and current athletic trainers to collaborate with other health professionals in a manner that optimizes the quality of care.Clinical Pharmacology in Athletic Training begins by addressing drug legislation and the legal aspects of the athletic trainer’s role in sport medication. The text provides an overview of pharmacokinetics and pharmacodynamics with an emphasis on concepts releTable of ContentsPart I. Foundational Pharmacology ConceptsChapter 1. Legal Aspects of Therapeutic Medication ManagementHealth Care Providers With Prescribing AuthorityThe Sports Medicine TeamFederal and State LawsDrug Development, Studies, and StandardsSummaryCase StudiesChapter 2. Administering Medications in the Athletic Training SettingAthletic Training ClinicGuidelines for Administering MedicationsPreventing Medication ErrorsSummaryCase StudiesChapter 3. Drug Names, Classification, and SafetyDrug NamesDrug ClassesDrug SafetyAdverse Drug Effects and Therapeutic MonitoringAllergic Drug ReactionsMedication Use ProcessDrug Information ResourcesSummaryCase StudiesChapter 4. PharmacokineticsBiopharmaceuticsDrug LiberationDrug AbsorptionDrug DistributionDrug MetabolismDrug EliminationPharmacokinetics and ExerciseSummaryCase StudiesChapter 5. PharmacodynamicsMechanism of ActionDrug ReceptorsDrug–Receptor BindingDrug–Receptor InteractionsDrug DosingDose ResponsesSummaryCase StudiesChapter 6. Drug Delivery, Dosages, and ProceduresDrug Delivery SystemsRoutes of AdministrationEnteral Drug DeliveryParenteral Drug DeliveryMucous Membrane Drug AdministrationTopical Drug AdministrationTransdermal Drug AdministrationMedication DosingClinical Procedures for Enteral Drug AdministrationSummaryCase StudiesPart II. Classes of Therapeutic MedicationsChapter 7. Drugs to Treat Pain: Nonopioid Analgesics and AnestheticsBiopsychosocial ModelDifferentiation of PainPathophysiology of PainAnalgesicsNonopioid Analgesic AgentsLocal AnestheticsTopical Analgesics: Creams, Gels, and OintmentsThe ATs’ Role in the Clinical Management of PainSummaryCase StudiesChapter 8. Drugs to Treat Pain: Opioid AnalgesicsAppropriate Use of Opioid AnalgesicsClasses of Opioid AnalgesicsSummaryCase StudiesChapter 9. Drugs to Treat Inflammation: Steroidal and Nonsteroidal Anti-InflammatoriesInflammatory ProcessControlling InflammationCorticosteroidsNonsteroidal Anti-Inflammatory DrugsSummaryCase StudiesChapter 10. Drugs to Treat Infection: AntibioticsIndications for UseMechanism of ActionTherapeutic EffectsRoutes of AdministrationPharmacokineticsPharmacodynamicsDosing GuidelinesAdverse EffectsIndications and PrecautionsPatient Education for Use of Antibacterial MedicationsSummaryCase StudiesPart III. Drugs for Treating Common ConditionsChapter 11. Drugs for Treating Asthma and Other Respiratory ConditionsRespiratory InfectionsAllergic Rhinitis and Other AllergiesAsthmaSummaryCase StudiesChapter 12. Drugs for Treating Cardiovascular ConditionsIschemic Chest Pain: Angina PectorisAtherosclerosis and Coronary Artery DiseaseAcute Coronary SyndromeHypertension and Hypertensive CrisisCardiac ArrhythmiasThromboembolismsSummaryCase StudiesChapter 13. Drugs for Treating Diabetes and Disordered Glucose MetabolismGlucose HomeostasisMetabolic DisordersAntidiabetic Agents for Managing Type 2 Diabetes MellitusInsulin for Managing Type 1 and Type 2 Diabetes MellitusDiabetes Care PlanSummaryCase StudiesChapter 14. Drugs for Treating Digestive DisordersNausea and VomitingDiarrheaConstipationGastroesophageal Reflux DiseaseGastritis and Peptic Ulcer DiseaseGastroenteritisFunctional Bowel Disorders: Inflammatory Bowel DiseaseSupportive Care and General Management of Digestive DisordersSummaryCase StudiesChapter 15. Drugs for Treating Common Musculoskeletal and Neurological ConditionsArticular (Joint) PainMusculotendinous PainNeck and Back PainFibromyalgiaComplex Regional Pain SyndromeHeadache DisordersSummaryCase StudiesChapter 16. Drugs for Treating Dermatological ConditionsProtective Barrier of the SkinPrinciples of Topical Dermatologic PharmacologyBacterial Skin and Soft-Tissue InfectionsFungal Skin InfectionsCandidiasisViral Skin Infections: Herpes Simplex and Molluscum ContagiosumAutoimmune Inflammatory Skin ConditionsSummaryCase StudiesChapter 17. Drugs for Treating Reproductive and Genitourinary ConcernsFamily Planning and ContraceptionShort-Acting Hormonal ContraceptivesLong-Acting Reversible ContraceptionBarrier MethodsEmergency ContraceptionRecommendations for Exercise During PregnancySexually Transmitted InfectionsReproductive and Urogenital ConcernsSummaryCase StudiesChapter 18. Drugs for Treating Mental Health ConditionsMental Health ConditionsBehavioral Health EmergenciesTreatment Options for Mental Health DisordersMood DisordersAnxiety DisordersStressor-Related DisordersSleep or Wakefulness DisordersNeurodevelopmental Disorders: Attention-Deficit/Hyperactivity DisorderEating DisordersSubstance-Related DisordersSummaryCase StudiesChapter 19. Drugs and Supplements to Enhance PerformanceSubstances Banned for CompetitionSupplements for Enhancing Musculoskeletal PerformanceSupplements for Treating Neurological ConditionsSupplements for Treating Skeletal ConditionsManipulation of Approved Medications to Enhance PerformanceSummaryCase StudiesChapter 20. Cannabis and CannabinoidsCannabisCannabinoidsAcute Effects of Cannabis UseChronic Effects of Cannabis UseAdverse Effects of CannabisCannabidiolMedical CannabinoidsResearch on Cannabinoid-Based MedicinesPerformance Effects and Sport RegulationRegulation of Cannabis UseClinical RecommendationsSummaryCase StudiesChapter 21. Drug Testing in SportDrug EducationThe Evolution of Drug Testing in SportSupplement StandardsThe Drug-Testing ProcessTesting for MarijuanaTesting for Anabolic SteroidsMasking AgentsResults of Drug TestingDrug ExemptionsSummaryCase StudiesChapter 22. Medications for SurgeryConcepts of AnesthesiaEffects of General AnesthesiaLevels of SedationStages of AnesthesiaTypes of AnesthesiaCommon Applications of Anesthesia in Sports MedicinePreparation for a Surgical ProcedureRecovery From a Surgical ProcedureAdverse Effects of AnesthesiaSummaryCase Studies

    3 in stock

    £63.00

© 2026 Book Curl

    • American Express
    • Apple Pay
    • Diners Club
    • Discover
    • Google Pay
    • Maestro
    • Mastercard
    • PayPal
    • Shop Pay
    • Union Pay
    • Visa

    Login

    Forgot your password?

    Don't have an account yet?
    Create account